Биосовместимое формованное изделие

Группа изобретений относится к области медицины, в частности к травматологии, и раскрывает биосовместимое формованное изделие, набор, содержащий множество формованных изделий, композицию и способ для получения указанного формованного изделия, а также применение указанного формованного изделия для поддержания формирования новой кости, в частности восстановления челюстной кости. Группа изобретений обеспечивает оптимальные условия для эффективного остеогенеза, возможности полной резорбции формованного изделия после завершения остеогенеза, в результате чего остается только восстановленная или новая кость. Формованное изделие выполнено в виде твердотельного изделия и подходит для установки на челюстную кость млекопитающего, предпочтительно человека. 5 н. и 23 з.п. ф-лы, 2 ил., 1 пр.

ЧАШКА ЭНДОПРОТЕЗА ТАЗОБЕДРЕННОГО СУСТАВА

Изобретение относится к медицине, ортопедии. Чашка эндопротеза тазобедренного сустава выполнена из композиционного материала. Материал содержит пористую матрицу из волокон кристаллического углерода с межслоевым расстоянием 3,58…3,62 ангстрема, при общем количестве волокна 20…80%. Материал-наполнитель состоит из кристаллического углерода с межслоевым расстоянием 3,42…3,44 ангстрема в количестве 50…70% и аморфного углерода в виде кокса в количестве 10…20% от общего объема пор матрицы. В аморфный углерод внедрены углеродные нанотрубки в количестве 0,05…1,0% от массы аморфного углерода. Изобретение позволяет повысить прочность эндопротеза до значений равных и выше максимальной прочности костной ткани человека. 2 з. п. ф-лы.

НОЖКА ЭНДОПРОТЕЗА ТАЗОБЕДРЕННОГО СУСТАВА

Изобретение относится к медицине, а именно ортопедии. Ножка эндопротеза тазобедренного сустава выполнена из композиционного материала. Материал содержит пористую матрицу из волокон кристаллического углерода с межслоевым расстоянием 3,58……3,62 ангстрема при общем количестве волокна 20……80% и материал-наполнитель, состоящий из кристаллического углерода с межслоевым расстоянием 3,42……3,44 ангстрема в количестве 50……70% и аморфного углерода в виде кокса в количестве 10……20% от общего объема пор матрицы. При этом в аморфный углерод внедрены углеродные нанотрубки в количестве 0,05……1,0% от массы аморфного углерода. Изобретение позволяет повысить прочность эндопротеза до значений, равных и выше максимальной прочности костной ткани человека. 2 з.п. ф-лы.

ТРЕХМЕРНЫЕ МАТРИЦЫ ИЗ СТРУКТУРИРОВАННОГО ПОРИСТОГО МОНЕТИТА ДЛЯ ТКАНЕВОЙ ИНЖЕНЕРИИ И РЕГЕНЕРАЦИИ КОСТИ И СПОСОБ ИХ ПОЛУЧЕНИЯ

Группа изобретений относится к трехмерной матрице из монетита со структурированной пористостью, способу синтеза указанной матрицы, форме для ее получения и применению матрицы из монетита для регенерации структуры кости. Заявленная матрица из монетита имеет в своей структуре вертикальные цилиндрические макропоры диаметром от 350 до 650 мкм, которые пересекают в продольном направлении матрицу с одного конца до другого и расположены на расстоянии друг от друга от 0,4 до 0,6 мм. Форма для получения указанной матрицы снабжена однородно распределенными зубцами диаметром 350-650 мкм, равномерно расположенными на расстоянии друг от друга 0,4-0,6 мм. Способ синтеза матрицы из монетита включает стадии смешивания основных фосфатов кальция, кислых фосфатов кальция, порообразующего агента и замедлителя схватывания и отверждения посредством добавления дистиллированной воды с образованием жидкой фазы, заполнения формы указанной жидкой фазой, стерилизации образованного материала-предшественника и его термического ...

Способ получения низкотемпературного биорезорбируемого композиционного материала на основе гидроксиапатита, армированного частицами магния с помощью электроимпульсного метода компактирования для применения в качестве имплантата при остеосинтезе

Изобретение относится к области медицины, а именно к травматологии и ортопедии, и раскрывает способ получения биорезорбируемого композиционного материала на основе гидроксиапатита, армированного частицами магния. Способ характеризуется тем, что включает смешение и помол исходных порошковых материалов, представляющих собой магний и гидроксиапатит, в атмосфере инертного газа в планетарной мельнице с последующим компактированием смеси электроимпульсным методом, при этом содержание фазы гидроксиапатита в порошковой смеси составляет 70-90 мас.%, а содержание фазы магния - 10-30 мас.%. Полученный композиционный материал на основе гидроксиапатита, армированного частицами магния, характеризуется прочностью не менее 250 МПа при сжатии и открытой пористостью не менее 10% и может быть использован качестве материала биорезорбируемого имплантата в остеосинтезе после различных травм. 5 ил., 5 табл.

ТРЕХМЕРНЫЕ МАТРИЦЫ ИЗ СТРУКТУРИРОВАННОГО ПОРИСТОГО МОНЕТИТА ДЛЯ ТКАНЕВОЙ ИНЖЕНЕРИИ И РЕГЕНЕРАЦИИ КОСТИ И СПОСОБ ИХ ПОЛУЧЕНИЯ

... 1. Трехмерная матрица из монетита со структурированной пористостью, отличающаяся тем, что имеет в своей структуре вертикальные цилиндрические макропоры диаметром от 350 до 650 мкм, которые пересекают в продольном направлении матрицу с одного конца до другого, причем эти макропоры находятся на расстоянии друг от друга от 0,4 до 0,6 мм. ! 2. Трехмерная матрица из монетита со структурированной пористостью по п.1, отличающаяся тем, что указанные макропоры имеют диаметр предпочтительно 500 мкм ±60 мкм. ! 3. Трехмерная матрица из монетита со структурированной пористостью по п.2, отличающаяся тем, что расстояние между макропорами составляет предпочтительно 0,5 мм ±60 мкм. ! 4. Трехмерная матрица из монетита со структурированной пористостью по п.1, отличающаяся тем, что содержание монетита в матрице составляет по меньшей мере 90%. ! 5. Трехмерная матрица из монетита со структурированной пористостью по п.4, отличающаяся тем, что содержание монетита в матрице составляет предпочтительно 95%. ! 6.

ИМПЛАНТАТ ДЛЯ ЗАМЕЩЕНИЯ КОСТНЫХ ДЕФЕКТОВ

НОЖКА ЭНДОПРОТЕЗА ТАЗОБЕДРЕННОГО СУСТАВА

ПОРИСТЫЕ СТРУКТУРЫ ИМПЛАНТАТОВ

... 1. Пористая структура, содержащая:ряд ветвей, причем каждая ветвь имеет:первый конец, второй конец и непрерывное удлиненное тело между указанными первым и вторым концами, причем указанное тело имеет толщину и длину; исодержащая ряд узлов, причем каждый узел содержит пересечение одного из концов первой ветви с телом второй ветви.2. Пористая структура по п.1, в которой первый и второй концы одной ветви или ряда ветвей расположены между телами двух других ветвей.3. Пористая структура по п.1, в которой тело одной или нескольких ветвей имеет ряд узлов.4. Пористая структура по п.1, в которой поперечное сечение по меньшей мере одного из концов ветви или ряда ветвей больше поперечного сечения части тела указанных ветви или ряда ветвей.5. Пористая структура по п.1, в которой по меньшей мере часть тела ветви или ряда ветвей является изогнутой.6. Пористая структура по п.1, в которой предусмотрена возможность соединения ряда ветвей друг с другом посредством спекания, сплавления, сваривания, пайки или ...

VERSTÄRKTE PORÖSE WIRBELSÄULENIMPLANTATE

Poröses keramisches/poröses mehrschichtiges Polymergerüst zur Reparatur und Regeneration von Gewebe

Porous bioceramic scaffolds and preparation method thereof

POLYMERE STRENGTHENED ANATOMICAL FIGURATION BIOACTIVE PROSTHESES

HYDROXYL APATITE COATING OF ALUMINA CERAMIC(S)

Biodegradable implant and method for manufacturing same

The present invention relates to a biodegradable implant including magnesium, and to a method for manufacturing same, wherein the magnesium includes manganese (Mn) as an impurity; and one selected from the group consisting of iron (Fe), nickel (Ni), and a mixture thereof, the content of the impurity is more than 0 and 1 or less weight parts relative to 100 weight parts of the magnesium, and {the one selected from the group consisting of iron (Fe), nickel (Ni), and a mixture thereof}/manganese (Mn) = more than 0 and less than 5.

A METHOD OF PRODUCING A MULTILAYER BODY BY COALESCENCE AND THE MULTILAYER BODY PRODUCED

A method of producing a multilayer body by coalescence, characterised in that the method comprises the steps of a) filling a pre-compacting mould with a start material in the form of powder, pellets, grains and the like, b) pre- compacting the start material at least once and c) compressing the material in a compression mould by at least one stroke, where a striking unit emits enough kinetic energy to form the body when striking the material inserted in the compression mould, causing coalescence of the material, d) at least one further material being inserted into the mould in the form of powder, pellets, grains and the like, either in step a), after compacting in step b) or after compressing the first material in step c), e) if necessary, further pre- compacting and/or compressing being performed after the insertion of the at least one further material.

COMPOSITE METALLIC MATERIALS, USES THEREOF AND PROCESS FOR MAKING SAME

A lightweight, high strength and corrosion resistant composite metallic m aterial is disclosed herein. The composite metallic material typically compr ises a high-to-weight ratio, low density core material; and a corrosion resi stant protective refractory metal layer. The method for making the composite metallic material comprises the steps of surface activating the core materi al and forming a refractory metal on the surface of the surface activated co re material by physical, chemical or electrochemical processes. Such a compo site material is suitable for making biomaterials, corrosion resistant equip ment and industrial electrodes.

BIOMIMETIC SCAFFOLDS

BIOMIMETIC FIBROUS POLYMER SCAFFOLDS

The invention provides a composition comprising a nanofiber polymer in which the fibers of the nanofiber polymer are aligned, and a molecule is covalently attached, either directly or through a linker, to the nanofiber polymer. This molecule is capable of either covalently or non-covalently attaching to a member selected from an extracellular matrix component, a growth factor, and combinations thereof. The invention also provides methods of making the composition and methods of using the compositions to add new tissue to a subject, such as a human.

BIOMATERIALS CONTAINING CALCIUM PHOSPHATE

Biomatériau à base de phosphate de calcium, notamment à base d'hydroxyapatite ou à base d'un matériau comprenant de l'hydroxyapatite tel que les phosphates de calcium biphasés et les ciments phosphocalciques, et son utilisation pour la fabrication d'un implant ou pour la pose d'une prothèse pour permettre la régénération du tissu osseux.

PREPARATION METHOD OF POROUS IMPLANT AND POROUS IMPLANT PREPARED THEREBY

The present invention relates to a preparation method of a medical porous implant and a porous implant prepared thereby, and more specifically, to a preparation method of a porous implant and a porous implant prepared thereby, wherein the preparation method comprises: a filling step of filling a material comprising a metal powder and a ceramic powder into a mold; and a sintering step of applying 100-2,000 kgf/cm2 of pressure to the material filled in the mold and simultaneously generating 500-2000 A of current and 3-7 V of voltage using a spark plasma sintering device so as to allow current to flow throughthe material, thereby sintering the material at 800-1,400 ℃. The porous implant is harmless to the human body, and can be prepared within a short time at low temperatures, thereby reducing manufacturing costs.

HOMOGENEOUS, STORAGE-RESISTANT DISPERSIONS

The invention relates to homogeneous, storage-resistant dispersions of calcium salts that are poorly soluble in water and/or polymers with at least one surfactant.

POROUS SCAFFOLD WITH CARBON-BASED NANOPARTICLES

The present invention refers to biocompatible porous scaffolds, especially bone regeneration scaffolds, comprising carbon-based nanoparticles, especially diamond nanoparticles, methods for the production of such biocompatible porous scaffolds, the use of such biocompatible porous scaffolds and methods for treating bone defects by inserting such biocompatible porous scaffolds comprising carbon-based nanoparticles into the bone defect.

Polymer-ceramic articulation

A ceramic-metal composite articulation is provided with substantial elimination of wear debris, wherein a ceramic material is provided with superior mechanical properties tailored for articulating with ceramic articulations having high flexural strength (greater than about 700 MPa), high fracture toughness (greater than about 7 MPam1/2) and a high Weibull modulus (greater than about 20), in comparison with presently available bio-ceramics such as alumina or zirconia. The mechanical property enhancement enables ceramic materials with greater reliability and significantly reduced in-vivo fracture risk to be obtained. Preliminary in-vitro wear performance, to several million cycles using established test protocols, of head/cup components in a prosthetic hip joint made from these ceramics also demonstrates the ultra low wear characteristics. These material properties substantially eliminate polyethylene (PE) wear debris mediated implant failures by offering an optimal combination of bio-mechanical ...

Роlуmеr-сеrаmiс аrtiсulаtiоn

А сеrаmiс-mеtаl соmpоsitе аrtiсulаtiоn is prоvidеd with substаntiаl еliminаtiоn оf wеаr dеbris, whеrеin а сеrаmiс mаtеriаl is prоvidеd with supеriоr mесhаniсаl prоpеrtiеs tаilоrеd fоr аrtiсulаting with сеrаmiс аrtiсulаtiоns hаving high flехurаl strеngth (grеаtеr thаn аbоut 700 МРа), high frасturе tоughnеss (grеаtеr thаn аbоut 7 МРаm1/2) аnd а high Wеibull mоdulus (grеаtеr thаn аbоut 20), in соmpаrisоn with prеsеntlу аvаilаblе biо-сеrаmiсs suсh аs аluminа оr zirсоniа. Тhе mесhаniсаl prоpеrtу еnhаnсеmеnt еnаblеs сеrаmiс mаtеriаls with grеаtеr rеliаbilitу аnd signifiсаntlу rеduсеd in-vivо frасturе risk tо bе оbtаinеd. Рrеliminаrу in-vitrо wеаr pеrfоrmаnсе, tо sеvеrаl milliоn сусlеs using еstаblishеd tеst prоtосоls, оf hеаd/сup соmpоnеnts in а prоsthеtiс hip jоint mаdе frоm thеsе сеrаmiсs аlsо dеmоnstrаtеs thе ultrа lоw wеаr сhаrасtеristiсs. Тhеsе mаtеriаl prоpеrtiеs substаntiаllу еliminаtе pоlуеthуlеnе (РЕ) wеаr dеbris mеdiаtеd implаnt fаilurеs bу оffеring аn оptimаl соmbinаtiоn оf biо-mесhаniсаl ...

Роlуmеr-сеrаmiс аrtiсulаtiоn

А сеrаmiс-mеtаl соmpоsitе аrtiсulаtiоn is prоvidеd with substаntiаl еliminаtiоn оf wеаr dеbris, whеrеin а сеrаmiс mаtеriаl is prоvidеd with supеriоr mесhаniсаl prоpеrtiеs tаilоrеd fоr аrtiсulаting with сеrаmiс аrtiсulаtiоns hаving high flехurаl strеngth (grеаtеr thаn аbоut 700 МРа), high frасturе tоughnеss (grеаtеr thаn аbоut 7 МРаm1/2) аnd а high Wеibull mоdulus (grеаtеr thаn аbоut 20), in соmpаrisоn with prеsеntlу аvаilаblе biо-сеrаmiсs suсh аs аluminа оr zirсоniа. Тhе mесhаniсаl prоpеrtу еnhаnсеmеnt еnаblеs сеrаmiс mаtеriаls with grеаtеr rеliаbilitу аnd signifiсаntlу rеduсеd in-vivо frасturе risk tо bе оbtаinеd. Рrеliminаrу in-vitrо wеаr pеrfоrmаnсе, tо sеvеrаl milliоn сусlеs using еstаblishеd tеst prоtосоls, оf hеаd/сup соmpоnеnts in а prоsthеtiс hip jоint mаdе frоm thеsе сеrаmiсs аlsо dеmоnstrаtеs thе ultrа lоw wеаr сhаrасtеristiсs. Тhеsе mаtеriаl prоpеrtiеs substаntiаllу еliminаtе pоlуеthуlеnе (РЕ) wеаr dеbris mеdiаtеd implаnt fаilurеs bу оffеring аn оptimаl соmbinаtiоn оf biо-mесhаniсаl ...

Способ получения биорезорбируемого материала на основе магния и гидроксиапатита с защитным многокомпонентным покрытием

Изобретение относится к области медицинского материаловедения и касается биорезорбируемых материалов. Предложен способ получения биорезорбируемого композитного материала с низкой скоростью коррозии на основе магния и гидроксиапатита. Способ включает гомогенное смешение порошков магния и гидроксиапатита, искровое плазменное спекание, плазменное электролитическое оксидирование. Порошки магния и гидроксиапатита при смешении дополнительно диспергируют ультразвуком, плазменное электролитическое оксидирование проводят в электролите, содержащем Na2SiO3⋅5H2O - 15 г/л, NaF - 5 г/л, с частотой поляризующих импульсов 300 Гц, сначала в течение 200 с при плотности тока 0,35 А/см2 на анодной составляющей до напряжения 300-350 В, с постоянным напряжением на катодной фазе -30 В, затем в течение 600 с анодную составляющую изменяют до 200 В, а катодную до -10 В. Далее наносят слой поликапролактона либо методом центрифугирования капельно в два этапа на скорости вращения 400 об/мин в течение 50 секунд, затем ...

Composite product for use e.g. in grinding devices or implants comprises a non-metallic inorganic matrix and a 3-dimensional, repeating, firmly-bonded metal network

A composite product having a non-metallic inorganic matrix and a 3-dimensional, repeating, firmly-bonded metal network is such that (1) the network makes up 5-30 volume % of the composite; (2) the network wires are macroscopically homogeneously and largely isometrically and isotropically distributed in the matrix; and (3) the matrix and network are at least partly interlocked and bonded with each other. An independent claim is also included for producing the composite by (A) filling or impregnating the cavities of a 3-dimensional repeating, firmly-bonded metal network with matrix material(s) or precursor(s) in melt-flowable, powder, thermoplastic or liquid form; and (B) exposing the matrix and network together, optionally with a rise in temperature.

Homogene lagerstabile Dispersionen

Die Erfindung betrifft homogene, lagerstabile Dispersionen von in Wasser schwer löslichen Calciumsalzen und/oder von Polymeren mit mindestens einem Tensid.

VERSTÄRKTE PORÖSE WIRBELSÄULENIMPLANTATE

Composition for improved bone fracture healing

A composition for use as an adjunct in orthopaedic surgery, for example in the treatment of i) delayed fracture healing in bone, manifesting as either a delayed or non-union; ii) a fusion procedure anywhere in the skeletal system, such as a, cranial, spinal, foot and ankle or upper limb and iii) for use as a bone void filler and to enhance bone in-filling in situations of bone loss, such as following combat, e.g., blast injuries, or non-combat related trauma such as road-traffic accidents. The composition comprises i) a parathyroid hormone or a derivative thereof, in an amount of 0.1 ng/ml to 50 ng/ml, (ii) one or more osteoclast inhibitors as defined therein and iii) a bone void filler as defined therein in a solid or liquid phase. The composition may further comprise stem cells. Also disclosed is a method of manufacturing said composition and a kit of parts for the manufacture thereof.

STRENGTHENED POROUS ONE SPINAL COLUMN IMPLANTS

METALLIC STRUCTURES INCORPORATING BIOACTIVE MATERIALS AND METHODS FOR CREATING THE SAME

Cartilage repair

This invention relates to compositions, methods of preparation thereof, and use thereof for cartilage repair.

A medical preparation

Semi-synthetic powder material, obtained by modifying the composition of a natural marine biomaterial, method for producing same, and applications thereof

The invention relates to a pulverulent semisynthetic material, derived from a natural marine biomaterial, namely the aragonitic inner layer of the shell of bivalve molluscs selected from the group comprising Pinctadines, notably Pinctada maxima, margaritifera, and Tridacnes, notably Tridacna gigas, maxima, derasa, tevaroa, squamosa, crocea, Hippopus hippopus, Hippopus porcelanus, in pulverulent form, with addition of insoluble and soluble biopolymers and calcium carbonate transformed by carbonation; it also relates to the method of preparation thereof and to the uses thereof.

SEMI-SYNTHETIC POWDER MATERIAL, OBTAINED BY MODIFYING THE COMPOSITION OF A NATURAL MARINE BIOMATERIAL, METHOD FOR PRODUCING SAME, AND APPLICATIONS THEREOF

L'invention porte sur un matériau semi-synthétique, pulvérulent, issu d'un biomatériau naturel marin qui est la couche aragonitique interne de la coquille de mollusques bivalves choisis dans le groupe comprenant des Pinctadines, notamment Pinctada maxima, margaritifera, et des Tridacnes, notamment Tridacna gigas,maxima, derasa, tevaroa, squamosa, crocea, Hippopus hippopus, Hippopus porcelanus, sous forme pulvérulente, additionné de bio-polymères insolubles et solubles et de carbonate de calcium transformé par carbonatation; elle porte également sur son procédé de préparation et sur ses utilisations.

THREE-DIMENSIONAL MATRICES OF STRUCTURED POROUS MONETITE FOR TISSUE ENGINEERING AND BONE REGENERATION, AND METHOD OF PREPARATION THEREOF

The present invention is in the field of tissue engineering and, specifically, that of osseous regeneration. The invention relates to a porous three-dimensional matrix of biocompatible monetite, of predefined structured porosity and reabsorbable, and method of synthesis capable of producing said material and applications thereof. These matrices constitute a perfect base for cell colonisation and proliferation permitting application thereof in tissue engineering and osseous regeneration by virtue of their advantageous properties of biocompatibility, reabsorption, osteoinduction, revascularisation, etc.

THREE-DIMENSIONAL MATRICES OF STRUCTURED POROUS MONETITE FOR TISSUE ENGINEERING AND BONE REGENERATION, AND METHOD OF PREPARATION THEREOF

The present invention is comprised within tissue engineering and, specifically, within bone regeneration. The invention relates to a porous three-dimensional matrix of monetite which is biocompatible, has structured porosity and is predefined and reabsorbable, as well as to the method of synthesis capable of producing said material and the applications thereof. These matrices are a perfect base for cell colonization and proliferation, allowing the application thereof in tissue engineering and bone regeneration as a result of their advantageous properties of biocompatibility, reabsorption, osteoinduction, revascularization, etc.

CARTILAGE REPAIR

This invention relates to compositions, methods of preparation thereof, and use thereof for cartilage repair.

REINFORCED BONE GRAFT SUBSTITUTES

One embodiment of a spinal spacer (10) includes a body (11) sized and configured for engagement between adjacent vertebrae (V). The body (11) includes two opposite faces (12, 14) and an outer surface (13) between the two faces (12, 14). In one embodiment, the body (11) includes deactivated bone material in synergistic combination with a bone growth factor. A sleeve (15) is disposed around the outer surface (13) of the body (11). The sleeve (15) is composed of a second material which is relatively stronger under compressive loads than the biocompatible material of the body (11). Also provided is a plurality of apertures (16) through the sleeve (15) in communication with the outer surface (13) of the body (11) for bone ingrowth. Means for attaching the sleeve to the endplates of adjoining vertebral bodies are also provided.

cimento composto substituto de enxerto ósseo e artigos dele originados

compósito biocompatível e seu uso

INJECTABLE COMPOSITE MATERIAL SUITABLE FOR USE AS A BONE SUBSTITUTE

ELECTROCHEMICAL IMPLANT FOR DELIVERING BENEFICIAL AGENTS

An apparatus for providing beneficial agents to the body is disclosed in one aspect of the invention as including an implant (10) and a device integrated with the implant to generate a beneficial agent, such as iodine, chlorine, or other halogens. The device includes electrodes (12a, 12b) to conduct an electrical current and a substantially solid layer (14) between the electrodes. An electrical current passes between the electrodes (12a, 12b) to electrochemically generate the beneficial agent. The implant may include a variety of devices to produce the beneficial agent, including for example an electrochemical cell (16), a capacitor, an electrochemical capacitor, a galvanic cell, or the like. Similarly, because of the solid state construction of the device, the device may, in certain embodiments, be incorporated into a load-bearing implant. This may be useful for use with certain types of implants, such as orthopedic implants.

Роlуmеr-сеrаmiс аrtiсulаtiоn

А сеrаmiс-mеtаl соmpоsitе аrtiсulаtiоn is prоvidеd with substаntiаl еliminаtiоn оf wеаr dеbris, whеrеin а сеrаmiс mаtеriаl is prоvidеd with supеriоr mесhаniсаl prоpеrtiеs tаilоrеd fоr аrtiсulаting with сеrаmiс аrtiсulаtiоns hаving high flехurаl strеngth (grеаtеr thаn аbоut 700 МРа), high frасturе tоughnеss (grеаtеr thаn аbоut 7 МРаm1/2) аnd а high Wеibull mоdulus (grеаtеr thаn аbоut 20), in соmpаrisоn with prеsеntlу аvаilаblе biо-сеrаmiсs suсh аs аluminа оr zirсоniа. Тhе mесhаniсаl prоpеrtу еnhаnсеmеnt еnаblеs сеrаmiс mаtеriаls with grеаtеr rеliаbilitу аnd signifiсаntlу rеduсеd in-vivо frасturе risk tо bе оbtаinеd. Рrеliminаrу in-vitrо wеаr pеrfоrmаnсе, tо sеvеrаl milliоn сусlеs using еstаblishеd tеst prоtосоls, оf hеаd/сup соmpоnеnts in а prоsthеtiс hip jоint mаdе frоm thеsе сеrаmiсs аlsо dеmоnstrаtеs thе ultrа lоw wеаr сhаrасtеristiсs. Тhеsе mаtеriаl prоpеrtiеs substаntiаllу еliminаtе pоlуеthуlеnе (РЕ) wеаr dеbris mеdiаtеd implаnt fаilurеs bу оffеring аn оptimаl соmbinаtiоn оf biо-mесhаniсаl ...

ПОРИСТЫЕ СТРУКТУРЫ ИМПЛАНТАТОВ

Группа изобретений относится к медицине и касается пористой структуры для медицинских имплантатов. Пористая структура содержит ряд ветвей, причем каждая ветвь имеет: первый конец, второй конец и непрерывное удлиненное тело между указанными первым и вторым концами, причем указанное тело имеет толщину и длину; и содержит ряд узлов, причем каждый узел содержит пересечение одного из концов первой ветви с телом второй ветви, при этом в каждом узле пересекаются не более двух ветвей. Также предложен способ изготовления пористой структуры для медицинских имплантатов. Группа изобретений обеспечивает возможность изготовления имплантатов, обладающих повышенной прочностью и необходимой для врастания клеток и ткани пористостью. 2 н. и 20 з.п. ф-лы, 61 ил.

ИМПЛАНТАТ ДЛЯ ЗАМЕЩЕНИЯ КОСТНЫХ ДЕФЕКТОВ

Изобретение относится к медицине, хирургии и ортопедии. Имплантат для замещения костных дефектов выполнен из углерод-углеродного композиционного материала. Материал содержит пористую матрицу из волокон кристаллического углерода с межслоевым расстоянием 3,58…3,62 ангстрема, при общем количестве волокна 20…80%. Материал-наполнитель состоит из кристаллического углерода с межслоевым расстоянием 3,42…3,44 ангстрема в количестве 50…70% и аморфного углерода в виде кокса в количестве 10…20% от общего объема пор матрицы. При этом в аморфный углерод внедрены углеродные нанотрубки в количестве 0,05…1,0% от массы аморфного углерода. Изобретение позволяет повысить эффективность применения имплантата для замещения костных дефектов путем повышения коэффициента запаса прочности кости при замещении ее дефекта. 2 з.п. ф-лы.

ИНЪЕЦИРУЕМЫЙ КОМПОЗИТНЫЙ МАТЕРИАЛ, ПРИГОДНЫЙ ДЛЯ ИСПОЛЬЗОВАНИЯ В КАЧЕСТВЕ ЗАМЕНИТЕЛЯ КОСТНОЙ ТКАНИ

Настоящее изобретение относится к медицине, конкретно к новому инъецируемому композитному материалу, пригодному для использования в качестве заменителя костной ткани. Композитный материал содержит реактивную керамическую фазу на основе трехзамещенного фосфата кальция и органическую фазу, содержащую гидрогель поливинилового спирта. Механические свойства, а также инъецируемость данного материала можно регулировать путем варьирования концентраций двух фаз. 4 н. и 5 з.п. ф-лы, 2 табл.

ПОРОШКООБРАЗНЫЙ, ПОЛУСИНТЕТИЧЕСКИЙ МАТЕРИАЛ, ПОЛУЧЕННЫЙ ИЗМЕНЕНИЕМ СОСТАВА МОРСКОГО ПРИРОДНОГО БИОМАТЕРИАЛА, СПОСОБ ЕГО ПРОИЗВОДСТВА И ПРИМЕНЕНИЕ

Группа изобретений относится к области медицины, а именно к порошкообразному полусинтетическому материалу для изготовления заменителей кости, инъекционных цементов или цементов для герметизации эндопротезов или для изготовления устройств для биоабсорбируемого остеосинтеза и формованных имплантатов, полученному из морского природного биоматериала, с добавками нерастворимых и растворимых биополимеров и карбоната кальция, преобразованного карбонатизацией, где природный морской биоматериал представляет собой арагонитовый внутренний слой раковины двустворчатых моллюсков, выбранный из группы, включающей Pinctadines и Tricdacnes, а также относится к способу получения порошкообразного полусинтетического материала; к применению материала в качестве костного заменителя с приготовлением непосредственно перед применением для заживления или восстановления потерь вещества, лечения ожогов, струпьев, язв, эритемных кожных повреждений или для изготовления устройств или литых имплантатов; к применению карбоната ...

МАТЕРИАЛ ЗАМЕНИТЕЛЯ КОСТНОЙ ТКАНИ

Изобретение относится к медицине. Описан двухфазный материал заменителя костной ткани на основе фосфата кальция / гидроксиапатита (САР/НАР), включающий ядро из спеченного CAP и как минимум один равномерный и закрытый эпитаксически нарастающий слой нанокристаллического НАР, нанесенный сверху на ядро из спеченного CAP, причем эпитаксически нарастающие нанокристаллы имеют такой же размер и морфологию, что и у минерала костей человека, то есть длину от 30 до 46 нм и ширину от 14 до 22 нм. Описан также способ получения материала заменителя костной ткани на основе САР/НАР, включающий этапы: а) изготовления ядра из спеченного материала CAP, b) погружения ядра из спеченного материала CAP в водный раствор при температуре от 10°С до 50°С для запуска процесса преобразования CAP в НАР, при помощи которого на поверхности ядра из спеченного материала CAP образуется равномерный и закрытый эпитаксически нарастающий слой нанокристаллического гидроксиапатита, причем эпитаксически нарастающие нанокристаллы ...

БИОСОВМЕСТИМЫЙ КОМПОЗИТ И ЕГО ПРИМЕНЕНИЕ

Изобретение относится к медицине, конкретно к композиционному материалу, включающему биосовместимое и биорассасывающееся стекло, биосовместимый и биорассасывающийся матричный полимер и связывающий агент, способный образовывать ковалентные связи. Композит включает компатибилизатор, при этом по меньшей мере 10% структурных звеньев компатибилизатора идентичны структурным звеньям матричного полимера, а молекулярная масса компатибилизатора меньше чем 30000 г/мол. Описано применение данного композита, медицинское устройство, содержащее указанный композит, и описан способ получения композита. Композит имеет по меньшей мере такой же высокий модуль, как модуль кортикального слоя кости. 4 н. и 16 з.п. ф-лы, 1 ил., 2 табл., 12 пр.

Биосовместимое формованное изделие

БИОСОВМЕСТИМЫЙ КОМПОЗИТ И ЕГО ПРИМЕНЕНИЕ

... 1. Композиционный материал, включающий- биосовместимое и биорассасывающееся стекло,- биосовместимый и биорассасывающийся матричный полимер и- связывающий агент, способный образовывать ковалентные связи,отличающийся тем, что он дополнительно включает компатибилизатор, при этом- по меньшей мере 10% структурных звеньев компатибилизатора идентичны структурным звеньям матричного полимера, а- молекулярная масса компатибилизатора меньше, чем 30000 г/мол.2. Композит по п.1, отличающийся тем, что биосовместимое и биорассасывающееся стекло находится в форме волокон.3. Композит по п.1 или 2, отличающийся тем, что по меньшей мере 30% структурных звеньев компатибилизатора идентичны структурным звеньям матричного полимера.4. Композит по п.1 или 2, отличающийся тем, что молекулярная масса компатибилизатора меньше, чем 10000 г/мол.5. Композит по п.1 или 2, отличающийся тем, что он дополнительно включает модификатор поверхности, способный защищать стекло и повышать увлажнение стекла.6. Композит по п.1 или ...

ЧАШКА ЭНДОПРОТЕЗА ТАЗОБЕДРЕННОГО СУСТАВА

Knochenersatzmaterialien, Verfahren zur Herstellung eines Knochenersatzmaterials sowie medizinische Kits zur Behandlung von Knochendefekten

POROUS CERAMIC/POROUS MULTILEVEL POLYMER STAND TO THE REPAIR AND REGENERATION OF FABRIC

INJECT-CASH KOMPOSITMATERIAL FOR USE AS BONE REPLACEMENT

BIOCOMPATIBLE GROUP AND ITS USE

A method of producing a multilayer body by coalescence and the multilayer body produced

Composite bone marrow graft material with method and kit

Semi-synthetic powder material, obtained by modifying the composition of a natural marine biomaterial, method for producing same, and applications thereof

The invention relates to a semi-synthetic powder material, derived from a natural marine biomaterial that is the inner aragonitic layer of the shell of bivalve molluscs chosen from the group comprising Pinctada, in particular Pinctada maxima and margaritifera, Tridacna, in particular Tridacna gigas, maxima, derasa, tevaroa, squamosa and crocea, Hippopus hippopus and Hippopus porcelanus, in powder form, supplemented with insoluble and soluble bio-polymers and calcium carbonate transformed by carbonation; it also relates to the method for preparing same and the uses thereof.

Porous implant structures

Porous biocompatible structures suitable for use as medical implants and methods for fabricating such structures are disclosed. The disclosed structures may be fabricated using rapid manufacturing techniques. The disclosed porous structures has a plurality of struts and nodes where no more than two struts intersect one another to form a node. Further, the nodes can be straight, curved, portions that are curved and/or straight. The struts and nodes can form cells which can be fused or sintered to at least one other cell to form a continuous reticulated structure for improved strength while providing the porosity needed for tissue and cell in-growth.

BONE SUBSTITUTE MATERIAL

The invention relates to: - a biphasic calcium phosphate/hydroxyapatite (CAP/HAP) bone substitute material comprising a sintered CAP core and at least one uniform and closed epitactically grown layer of nanocrystalline HAP deposited on top of the sintered CAP core, whereby the epitactically grown nanocrystals have the same size and morphology as human bone mineral, i.e. a length of 30 to 46 nm and a width of 14 to 22 nm, - a process of preparing the above CAP/HAP bone substitute material comprising the steps of a) preparing a sintered CAP core material, b) immersing the sintered CAP core material in an aqueous solution at a temperature between 10°C and 50°C to start the transformation process of CAP to HAP whereby a uniform and closed epitactic grown layer of nanocrystalline hydroxyapatite will be formed on the CAP core material surface, the epitactically grown nanocrystals having the same size and morphology as human bone mineral, c) stopping the transformation by separating solid material ...

POROUS IMPLANT STRUCTURES

Porous biocompatible structures suitable for use as medical implants and methods for fabricating such structures are disclosed. The disclosed structures may be fabricated using rapid manufacturing techniques. The disclosed porous structures has a plurality of struts and nodes where no more than two struts intersect one another to form a node. Further, the nodes can be straight, curved, portions that are curved and/or straight. The struts and nodes can form cells which can be fused or sintered to at least one other cell to form a continuous reticulated structure for improved strength while providing the porosity needed for tissue and cell in-growth.

REINFORCED BONE GRAFT SUBSTITUTES

One embodiment of a spinal spacer (10) includes a body (11) sized and configured for engagement between adjacent vertebrae (V). The body (11) includes two opposite faces (12, 14) and an outer surface (13) between the two faces (12, 14). In one embodiment, the body (11) includes deactivated bone material in synergistic combination with a bone growth factor. A sleeve (15) is disposed around the outer surface (13) of the body (11). The sleeve (15) is composed of a second material which is relatively stronger under compressive loads than the biocompatible material of the body (11). Also provided is a plurality of apertures (16) through the sleeve (15) in communication with the outer surface (13) of the body (11) for bone ingrowth. Means for attaching the sleeve to the endplates of adjoining vertebral bodies are also provided.

METHOD FOR MANUFACTURING CALCIUM OCTAVUS PHOSPHATE MOLDED ARTICLE

A method of producing a composite body by coalescence and the composite body produced

A method of producing a composite body by coalescence, wherein the method comprises the steps of (a) filling a pre-compacting mould with composite material in the form of powder, pellets, grains and the like, (b) pre-compacting the material at least once and (c) compressing the material in a compression mould by at least one stroke, where a striking unit emits enough kinetic energy to form the body when striking the material inserted in the compression mould, causing coalescence of the material. A method of producing a composite body by coalescence, wherein the method comprises compressing material in the form of a solid composite body in a compression mould by at least one stroke, where a striking unit emits enough energy to cause coalescence of the material in the body. Products obtained by the inventive methods.

SYSTEM COMPRISING A) POORLY WATER-SOLUBLE CALCIUM SALTS AND/OR COMPOSITE MATERIALS CONTAINING THE SAME, AND B) EASILY WATER-SOLUBLE CALCIUM SALTS AND/OR PHOSPHATE SALTS

The invention relates to a system which is characterized in that the same comprises a) poorly water-soluble calcium salts and/or composite materials containing the same, and b) easily water-soluble calcium salts and/or phosphate salts. Said system is particularly suitable for quickly promoting the restoration of bones and tooth material, especially enamel and dentin.

POROUS SCAFFOLD WITH CARBON-BASED NANOPARTICLES

A biocompatible porous scaffolds, especially bone regeneration scaffolds, comprising carbon-based nanoparticles, especially diamond nanoparticles, methods for the production of such biocompatible porous scaffolds, the use of such biocompatible porous scaffolds and methods for treating bone defects by inserting such biocompatible porous scaffolds comprising carbon-based nanoparticles into the bone defect.

Роlуmеr-сеrаmiс аrtiсulаtiоn

А сеrаmiс-mеtаl соmpоsitе аrtiсulаtiоn is prоvidеd with substаntiаl еliminаtiоn оf wеаr dеbris, whеrеin а сеrаmiс mаtеriаl is prоvidеd with supеriоr mесhаniсаl prоpеrtiеs tаilоrеd fоr аrtiсulаting with сеrаmiс аrtiсulаtiоns hаving high flехurаl strеngth (grеаtеr thаn аbоut 700 МРа), high frасturе tоughnеss (grеаtеr thаn аbоut 7 МРаm1/2) аnd а high Wеibull mоdulus (grеаtеr thаn аbоut 20), in соmpаrisоn with prеsеntlу аvаilаblе biо-сеrаmiсs suсh аs аluminа оr zirсоniа. Тhе mесhаniсаl prоpеrtу еnhаnсеmеnt еnаblеs сеrаmiс mаtеriаls with grеаtеr rеliаbilitу аnd signifiсаntlу rеduсеd in-vivо frасturе risk tо bе оbtаinеd. Рrеliminаrу in-vitrо wеаr pеrfоrmаnсе, tо sеvеrаl milliоn сусlеs using еstаblishеd tеst prоtосоls, оf hеаd/сup соmpоnеnts in а prоsthеtiс hip jоint mаdе frоm thеsе сеrаmiсs аlsо dеmоnstrаtеs thе ultrа lоw wеаr сhаrасtеristiсs. Тhеsе mаtеriаl prоpеrtiеs substаntiаllу еliminаtе pоlуеthуlеnе (РЕ) wеаr dеbris mеdiаtеd implаnt fаilurеs bу оffеring аn оptimаl соmbinаtiоn оf biо-mесhаniсаl ...

A METHOD OF PRODUCING A COMPOSITE BODY BY COALESCENCE AND THE COMPOSITE BODY PRODUCED

A method of producing a composite body by coalescence, wherein the method comprises the steps of a) filling a pre-compacting mould with composite material in the form of powder, pellets, grains and the like, b) pre-compacting the material at least once and c) compressing the material in a compression mould by at least one stroke, where a striking unit emits enough kinetic energy to form the body when striking the material inserted in the compression mould, causing coalescence of the material. A method of producing a composite body by coalescence, wherein the method comprises compressing material in the form of a solid composite body in a compression mould by at least one stroke, where a striking unit emits enough energy to cause coalescence of the material in the body. Products obtained by the inventive methods.

解剖学的に正確なポリマー強化生体活性人工器官

... 解剖精度および骨順化が重要である頭蓋顎顔面形成再建術などの骨再建術用のカストマイズ移植片。この移植片は、多孔質表面層と、相互貫入相複合材の靱性内部コアとを含む。多孔質表面層は、生物適合性、組織内発育および移植片安定性を強化する。靱性内部コアは、高破壊靱性および低弾性率によって移植片の機械的特性を改善する。移植片の解剖精度は、安定な被移植体骨-移植片境界面を維持するために必要とされる術中処置を最小にする。 ...

БИОМАТЕРИАЛЫ НА ОСНОВЕ ФОСФАТА КАЛЬЦИЯ

... 1. Биоматериал, содержащий подложку на основе фосфата кальция, пропитанную раствором по меньшей мере одного коагулянта, представляющего собой производное кальция, причем подложка выбрана из гидроксиапатита и ВСР, а коагулянт находится в виде водного раствора с концентрацией в интервале от 1 до 50 ммоль/л, причем соотношение между раствором коагулянта и НА или ВСР составляет от 0,5 до 5 об./об. раствора коагулянта по отношению к объему НА или ВСР. ! 2. Биоматериал по п.1, в котором коагулянт, представляющий собой производное кальция, содержится с соотношением в интервале от 2,5 до 60 мкмоль кальция на грамм НА или ВСР и предпочтительно от 5 до 40 мкмоль кальция на грамм НА или ВСР. ! 3. Биоматериал по п.1 или 2, в котором коагулянт представляет собой CaCl2. ! 4. Биоматериал по п.1 или 2, в котором подложка представляет собой монолитное тело. ! 5. Биоматериал по п.1 или 2, в котором подложка находится в форме гранул, с гранулометрическим составом предпочтительно в интервале от 40 до 500 мкм ...

СПОСОБ ИЗГОТОВЛЕНИЯ ИЗДЕЛИЯ ИЗ ПОЛИМЕРНОГО МАТЕРИАЛА ПУТЕМ КОАЛЕСЦЕНЦИИ И ИЗГОТОВЛЕННОЕ ИЗДЕЛИЕ ИЗ ПОЛИМЕРНОГО МАТЕРИАЛА

... 1. Способ изготовления изделия из полимерного материала путем коалесценции, отличающийся тем, что а) заполняют формы полимерным материалом в виде порошка, гранул, зерен и т.п. для предварительного уплотнения, b) предварительно уплотняют материал, по меньшей мере, один раз и с) прессуют материал в пресс-форме посредством, по меньшей мере, одного удара, при этом ударное устройство выделяет достаточное количество кинетической энергии для формования изделия при ударном воздействии на материал, введенный в пресс-форму, вызывающем коалесценцию материала. 2. Способ по п.1, отличающийся тем, что для предварительного уплотнения и прессования используют одну и ту же форму. 3. Способ по любому из предшествующих пунктов, предназначенный для получения изделия из полиэтилена с ультравысокой молекулярной массой, отличающийся тем, что материал предварительно уплотняют при давлении не менее приблизительно 0,25·108Н/м2, в воздушной среде и при комнатной температуре. 4. Способ по п.3, отличающийся тем, что ...

НОЖКА ЭНДОПРОТЕЗА ТАЗОБЕДРЕННОГО СУСТАВА

Изобретение относится к медицине, а именно ортопедии. Ножка эндопротеза тазобедренного сустава выполнена из композиционного материала. Материал содержит пористую матрицу из волокон кристаллического углерода с межслоевым расстоянием 3,58……3,62 ангстрема при общем количестве волокна 20……80% и материал-наполнитель, состоящий из кристаллического углерода с межслоевым расстоянием 3,42……3,44 ангстрема в количестве 50……70% и аморфного углерода в виде кокса в количестве 10……20% от общего объема пор матрицы. При этом в аморфный углерод внедрены углеродные нанотрубки в количестве 0,05……1,0% от массы аморфного углерода. Изобретение позволяет повысить прочность эндопротеза до значений, равных и выше максимальной прочности костной ткани человека. 2 з.п. ф-лы.

Головка эндопротеза тазобедренного сустава

Изобретение относится к медицине, ортопедии. Головка эндопротеза тазобедренного сустава выполнена из композиционного материала. Материал содержит пористую матрицу из волокон кристаллического углерода с межслоевым расстоянием 3,58…3,62 ангстрема, при общем количестве волокна 20…80%. Материал-наполнитель состоит из кристаллического углерода с межслоевым расстоянием 3,42…3,44 ангстрема в количестве 50…70% и аморфного углерода в виде кокса в количестве 10…20% от общего объема пор матрицы. В аморфный углерод внедрены углеродные нанотрубки в количестве 0,05…1,0% от массы аморфного углерода. Изобретение позволяет повысить прочность эндопротезов до значений, равных и выше максимальной прочности костной ткани человека. 2 з.п. ф-лы.

ПОРОШКООБРАЗНЫЙ, ПОЛУСИНТЕТИЧЕСКИЙ МАТЕРИАЛ, ПОЛУЧЕННЫЙ ИЗМЕНЕНИЕМ СОСТАВА МОРСКОГО ПРИРОДНОГО БИОМАТЕРИАЛА, СПОСОБ ЕГО ПРОИЗВОДСТВА И ПРИМЕНЕНИЕ

КОМПОЗИТНЫЙ МАТЕРИАЛ ДЛЯ ИМПЛАНТАТОВ

Composition for improved bone fracture healing

MARROW SUBSTITUTE COMPOSITE MATERIAL, PROCEDURE TOO ITS HERSTELLLUNG AND KITS

BIOREACTIVE MATERIAL FUER KOMPOSIT PROSTHESES OR - IMPLANTS.

REPLACEMENT FOR STRENGTHENED KNOCHENTRANSPLANT

MEDICAL INSTRUMENTS WITH METAL POLYMER GROUP

Composition for improved bone fracture healing

Abstract The present invention relates to a composition for use as an adjunct in orthopaedic surgery, such as in the treatment of i) delayed fracture healing in bone, 5 manifesting as either a delayed or non-union; ii) in a fusion procedure anywhere in the skeletal system, such as cranial, spinal, foot and ankle, or upper limb; and iii) for use as a bone void filler and to enhance bone in-filling in situations of bone loss such as following combat, e.g. blast injuries, or non-combat related trauma such as road traffic accidents.

Biocompatible molded part

The invention relates to a biocompatible molded part for supporting new bone formation, in particular the reformation of a jaw bone or a jaw bone portion in a mammal, preferably a human, wherein the molded part is suitable to be placed on the jaw bone and is designed as a solid body. The invention also relates to a composition for producing a biocompatible molded part, a method for producing a biocompatible molded part, a use of a biocompatible molded part and a kit comprising a plurality of molded parts.

Composite bone graft substitute cement and articles produced therefrom

The invention provides a particulate composition adapted for forming a bone graft substitute cement upon mixing with an aqueous solution, including i) a calcium sulfate hemihydrate powder having a bimodal particle distribution and a median particle size of about 5 to about 20 microns, wherein the calcium sulfate hemihydrate is present at a concentration of at least about 70 weight percent based on the total weight of the particulate composition; ii) a monocalcium phosphate monohydrate powder; and iii) a -tricalcium phosphate powder having a median particle size of less than about 20 microns. Bone graft substitute cements made therefrom, a bone graft substitute kit comprising the particulate composition, methods of making and using the particulate composition, and articles made from the bone graft substitute cement are also provided.

Bone substitute material

The invention relates to: - a biphasic calcium phosphate/hydroxyapatite (CAP/HAP) bone substitute material comprising a sintered CAP core and at least one uniform and closed epitactically grown layer of nanocrystalline HAP deposited on top of the sintered CAP core, whereby the epitactically grown nanocrystals have the same size and morphology as human bone mineral, i.e. a length of 30 to 46 nm and a width of 14 to 22 nm, - a process of preparing the above CAP/HAP bone substitute material comprising the steps of a) preparing a sintered CAP core material, b) immersing the sintered CAP core material in an aqueous solution at a temperature between 10°C and 50°C to start the transformation process of CAP to HAP whereby a uniform and closed epitactic grown layer of nanocrystalline hydroxyapatite will be formed on the CAP core material surface, the epitactically grown nanocrystals having the same size and morphology as human bone mineral, c) stopping the transformation by separating solid material ...

Three-dimensional matrices of structured porous monetite for tissue engineering and osseous regeneration, and method for the preparation thereof

Process for producing particles loaded with growth factors, and the particles obtained in this way

A METHOD OF PRODUCING A METAL BODY BY COALESCENCE AND THE METAL BODY PRODUCED

A method of producing a metal body by coalescence, wherein the method comprises the steps of a) filling a pre-compacting mould with metal material in the form of powder, pellets, grains and the like, b) pre-compacting the material at least once and c) compressing the material in a compression mould by at least one stroke, where a striking unit emits enough kinetic energy to form the body when striking the material inserted in the compression mould, causing coalescence of the material. A method of producing a metal body by coalescence, wherein the method comprises compressing material in the form of a solid metal body in a compression mould by at least one stroke, where a striking unit emits enough energy to cause coalescence of the material in the body. Products obtained by the inventive methods.

BONE SUBSTITUTE MATERIAL

The invention relates to: - a biphasic calcium phosphate/hydroxyapatite (CAP/HAP) bone substitute material comprising a sintered CAP core and at least one uniform and closed epitactically grown layer of nanocrystalline HAP deposited on top of the sintered CAP core, whereby the epitactically grown nanocrystals have the same size and morphology as human bone mineral, i.e. a length of 30 to 46 nm and a width of 14 to 22 nm, - a process of preparing the above CAP/HAP bone substitute material comprising the steps of a) preparing a sintered CAP core material, b) immersing the sintered CAP core material in an aqueous solution at a temperature between 10°C and 50°C to start the transformation process of CAP to HAP whereby a uniform and closed epitactic grown layer of nanocrystalline hydroxyapatite will be formed on the CAP core material surface, the epitactically grown nanocrystals having the same size and morphology as human bone mineral, c) stopping the transformation by separating solid material ...

BIOREACTIVE MATERIAL FOR PROSTHESIS OR COMPOSITE IMPLANTS

Matériau bioréactif du type verre ou verre partiellement cristallisé, pour prothèse osseuse ou implant dentaire, se soudant par liaison chimique avec un tissu osseux, cette liaison ne présentant pas de défauts d'ossification et ayant à la fois une faible épaisseur et une résistance mécanique très améliorée, ledit matériau ayant un faible coefficient de dilatation et une très bonne adhérence sur des matériaux de structure, tel Ti, pouvant être utilisés pour la confection de pièces composites, caractérisé en ce qu'il contient en % poids, 5 à 14 de Na2O, 0 à 12% de P2O5, 49 à 57% de SiO2, le solde étant constitué d'au plus 33% d'un mélange de CaO et CaF2, ce dernier étant compris entre 0,5 et 7%.

COMPOSITE MATERIAL BIOREACTIF FOR PROSTHESIS OR IMPLANTS.

Matériau bioréactif pour prothèse ou implants composites.

Matériau bioréactif du type verre ou verre partiellement cristallisé, pour prothèse osseuse ou implant dentaire, se soudant par liaison chimique avec un tissu osseux, cette liaison ne présentant pas de défauts d'ossification et ayant à la fois une faible épaisseur et une résistance mécanique très améliorée, ledit matériau ayant un faible coefficient de dilatation et une très bonne adhérence sur des matériaux de structure, tel Ti, pouvant être utilisés pour la confection de pièces composites, caractérisé en ce qu'il contient en % poids, 5 à 14 de Na2 O, 0 à 12% de P2 O5 , 49 à 57% de SiO2 , le solde étant constitué d'au plus 33% d'un mélange de CaO et CaF2 , ce dernier étant compris entre 0,5 et 10%.

POROUS, LOAD-BEARING, CERAMIC OR METAL IMPLANT

A method and apparatus for adjusting the modulus of elasticity, flexural strength, or porosity of metal and ceramic implants is disclosed in one embodiment of the invention as including a green tape comprising metal or ceramic particles, or a combination thereof, for incorporation into a solid implant structure (44). Apertures (32) are cut in selected regions of the green tape (34) in order to create a desired pore structure in the solid implant structure (44). This pore structure may be designed to give the solid structure (44) a desired modulus of elasticity, flexural strength, or porosity as well as to promote bone ingrowth. The green tape (34) may then be layered in an orientation that will provide the desired pore structure and the metal or ceramic particles and layers may be fused together to create the solid implant structure (44).

PROCESSES FOR MAKING CERAMIC MEDICAL DEVICES

A process for making a sintered ceramic medical device, comprising providing an unsintered ceramic composition, forming the unsintered ceramic composition into a green body that comprises unsintered ceramic, irradiating the green body with microwave radiation, and cooling the sintered body. The microwave radiation has a frequency capable of heating the unsintered ceramic to a temperature sufficient to sinter the green body, thereby preparing a sintered ceramic medical device. A medical device comprising volumetrically sintered ceramic, and a volumetrically sintered ceramic are also disclosed.

Biodegradable implant and method for manufacturing same

This invention relates to a biodegradable implant including magnesium, wherein the magnesium contains, as impurities, (i) manganese (Mn); and (ii) one selected from the group consisting of iron (Fe), nickel (Ni) and mixtures of iron (Fe) and nickel (Ni), wherein the impurities satisfy the following condition: 0</(i)≦5, and an amount of the impurities is 1 part by weight or less but exceeding 0 parts by weight based on 100 parts by weight of the magnesium, and to a method of manufacturing the same.

Bone regeneration materials based on combinations of monetite and other bioactive calcium and silicon compounds

The present invention incorporates new materials for bone regeneration, methods for their manufacture, and application in traumatology surgery, maxillo facial surgery, dental surgery, orthognatic surgery, endodontics, ophthalmology, neurosurgery and/or osteoporotic processes, and other indications where bone regeneration is required. In particular, the present invention incorporates synthetic materials with a 20% to a 95%, preferably between 40% and 90% in mass of monetite [Ca 1-X M X HPO 4 , where 0≦x≦0.05, and where M can be a divalent metallic ion], and which in their final composition incorporate between 5% and 80%, preferably between 0% and 60%, in mass of bioactive calcium compounds chosen from calcium phosphates and between 5% and 80% in total mass of bioactive silicon compounds chosen from calcium silicates and/or bioactive silica glasses and gels.

Method of Making Porous Metal Articles

In one embodiment, the present invention may be a method of making a porous biocompatible metal article by combining a metal powder with a homogenizing aid to form metal granules, including blending the metal granules and an extractable particulate to form a composite, forming the composite into a green article, removing the extractable particulate from the green article to form a metal matrix and pore structure, and sintering the metal matrix and pore structure. Furthermore the present invention may include a second homogenizing aid combined with the extractable particulate. The present invention also includes shaping the metal matrix and pore structure with or without the use of a binder.

Composites of hydroxyapatite and calcium carbonate and related methods of preparation and use

Carbonated calcium phosphate compositions and methods of preparation, affording enhanced biophysical properties.

Injectible, biocompatible synthetic bone growth composition

An injectible, biocompatible synthetic bone growth composition comprising a mineralized collagen and a calcium sulfate component. The composition is formed into injectible formulation that may be provided at the site of a skeletal defect via minimally invasive manner. An osteoinductive component may be further added, either before or after forming the unitary article. The composition may be formulated as a paste or putty and facilitates bone growth and/or repair.

Cartilage Repair

This invention relates to compositions, methods of preparation thereof, and use thereof for cartilage repair.

Multicomponent and biocompatible nanocomposite materials, methods of synthesizing same and applications of same

One aspect of the present invention relates to a method of synthesizing a multicomponent and biocompatible nanocomposite material, which includes: synthesizing a gold/hydroxyapatite (Au/HA) catalyst; distributing the Au/HA catalyst into a thin film; and heating the thin film in a reactor with a carbon source gas to perform radio frequency chemical vapor deposition (RF-CVD) to form the nanocomposite material, where the nanocomposite material includes a graphene structure and Au/HA nanoparticles formed by the Au/HA catalyst and distributed within the graphene structure. In another aspect, a multicomponent and biocompatible nanocomposite material includes: a graphene structure formed with a plurality of graphene layers and Au/HA nanoparticles distributed within the graphene structure. The nanocomposite material is formed by heating an Au/HA catalyst thin film with a carbon source gas to perform radio frequency chemical vapor deposition (RF-CVD).

Glass/carbon nanotube composite material for bone graft support

A composition for bone graft structural support, including a bioglass matrix and a plurality of carbon nanotubes dispersed throughout the bioglass matrix. The carbon nanotubes are generally cylindrical and are substantially between about 10 nanometer and about 20 nanometers in diameter and are substantially between about 5 nanometers and about 13 nanometers in length.

OSTEOGENIC DEVICES AND METHODS OF USE THEREOF FOR REPAIR OF ENDOCHONDRAL BONE, OSTEOCHONDRAL AND CHONDRAL DEFECTS

Disclosed herein are improved osteogenic devices and methods of use thereof for repair of bone and cartilage defects. The devices and methods promote accelerated formation of repair tissue with enhanced stability using less osteogenic protein than devices in the art. Defects susceptible to repair with the instant invention include, but are not limited to: critical size defects, non-critical size defects, non-union fractures, fractures, osteochondral defects, subchondral defects, and detects resulting from degenerative diseases such as osteochondritis dessicans. 1. A device for inducing local bone or cartilage formation , comprising:osteogenic protein;matrix derived from non-synthetic, non-polymeric material; andbinding agent.2. The device of claim 1 , wherein said osteogenic protein is selected from the group consisting of: OP-1 claim 1 , OP-2 claim 1 , OP-3 claim 1 , BMP3 claim 1 , BMP4 claim 1 , BMP5 claim 1 , BMP6 claim 1 , BMP9 claim 1 , BMP10 claim 1 , BMP11 claim 1 , BMP12 claim 1 , BMP15 claim 1 , BMP16. DPP claim 1 , Vg1 claim 1 , Vgr claim 1 , 60A protein claim 1 , GDF1 claim 1 , GDF3 claim 1 , GDF5 claim 1 , GDF6 claim 1 , GDF7 claim 1 , GDF8 claim 1 , GDF9 claim 1 , GDF10 claim 1 , GDF11 claim 1 , and amino acid sequence variants of each of the foregoing.3. The device of claim 1 , wherein said osteogenic protein is selected from the group consisting of: OP-1 claim 1 , OP-2 claim 1 , BMP2 claim 1 , BMP4 claim 1 , BMP5 claim 1 , BMP6 claim 1 , and amino acid sequence variants of each of the foregoing.4. The device of claim 1 , wherein said osteogenic protein comprises an amino acid sequence having at least 70% homology with the C-terminal 102-106 amino acids claim 1 , including the conserved seven cysteine domain claim 1 , of human OP-1.5. The device of claim 1 , wherein said osteogenic protein is OP-1.6. The device of claim 1 , wherein said device comprises at least two different osteogenic proteins.7. The device of claim 1 , wherein said matrix is ...

IMPLANTABLE MATERIALS FOR BONE REPAIR

The invention features fiber reinforced bone repair putties and fiber reinforced pliable lyophilized implants which are useful for the treatment of bone defects. The putties and lyophilized implants include ceramic particles. The formulations of the invention can exhibit reduced migration of the ceramic particles, and are mechanically strengthened so the materials can be aggressively manipulated by a physician during an implantation procedure without tearing or puncturing. 1. A bone repair putty comprising:(i) from 25% to 65% (w/w) particulate bone graft substitute or particulate demineralized bone matrix having a mean particle size of from 100 μm to 1000 μm;(ii) from 30% to 75% (w/w) hydrogel carrier for suspending said particulate bone graft substitute; and(iii) from 0.2% to 2% (w/w) fibers, said fibers having an average length of from 0.5 to 15 mm,wherein said bone repair putty is non-setting and malleable and wherein the migration of said ceramic particles from said putty is reduced.2. The bone repair putty of claim 1 , wherein said hydrogel carrier comprises a dispersing agent selected from glycerin claim 1 , polyethylene glycol claim 1 , N-methylpyrrolidone claim 1 , and triacetin; a polymer selected from sodium carboxymethylcellulose claim 1 , polyvinylalcohol claim 1 , hydroxyethyl cellulose claim 1 , hydroxypropyl methylcellulose claim 1 , methylcellulose claim 1 , ethylcellulose claim 1 , and hyaluronic acid; and water.3. The bone repair putty of claim 2 , wherein said bone repair putty comprises:(i) from 3% to 10% (w/w) a dispersing agent selected from glycerin, polyethylene glycol, N-methylpyrrolidone, and triacetin;(ii) from 0.5% to 2.0% (w/w) a polymer selected from sodium carboxymethylcellulose, polyvinylalcohol, hydroxyethyl cellulose, hydroxypropyl methylcellulose, methylcellulose, ethylcellulose, and hyaluronic acid;(iii) from 40% to 60% (w/w) particulate calcium phosphate;(iv) from 25% to 55% (w/w) water; and(v) from 0.2% to 2% (w/w) fibers, said ...

Particulate substances comprising ceramic particles for delivery of biomolecules

A particulate substance comprising particles of a ceramic matrix bearing a functional group, the functional group being capable of promoting penetration of the particles into cells, and a biomolecule disposed within pores of the particles, the biomolecule being releasable from the particles by dissolution of the ceramic matrix.

TISSUE REPAIR AND REPLACEMENT

Tissue fixation devices are provided. The devices include a first component and a second component, the components having different rates of in vivo degradation. The first component and second component are arranged so that, upon degradation of one of the components, the other component provides a scaffold into which bone can grow. 148.-. (canceled)49. A biodegradable tissue fixation device , comprising:a first component having an outer surface and having interconnecting pores; anda second component disposed in the pores of the first component, such that the first component is non-porous,wherein the second component further forms a non-porous layer that covers the outer surface of the first component except in defined areas,wherein the first component has a higher rate of in vivo degradation than the second component.50. The device of claim 49 , wherein the first component has a pore size of about 20-2000 microns.51. The device of claim 49 , wherein the first component has a porosity of about 10-90%.52. The device of claim 49 , wherein one of the first and second components comprises a ceramic.53. The device of claim 52 , wherein the other component comprises a polymer.54. The device of claim 53 , wherein the first component comprises ceramic and the second component comprises polymer.55. The device of claim 49 , wherein there is at least an 8 week difference between the rate of in vivo degradation of the first and second components.56. The device of claim 55 , wherein the rate of in vivo degradation of the first and second components differs by about 12 months to 2 years.57. The device of claim 49 , wherein at least one of the first and second components includes a therapeutic additive.58. The device of claim 49 , wherein at least one of the first and second components comprises a polymer selected from the group consisting of poly(a-hydroxy acids) claim 49 , polyhydroxyalkonates claim 49 , polycarbonates claim 49 , polyacetals claim 49 , polyorthoesters claim 49 , ...

Bone substitute material

The invention relates to: —a porous biphasic calcium phosphate/hydroxyapatite (CAP/HAP) bone substitute material comprising a sintered CAP core and at least one uniform and closed epitactically grown layer of nanocrystalline HAP deposited on top of the sintered CAP core, whereby the epitactically grown nanocrystals have the same size and morphology as human bone mineral, i.e. a length of 30 to 46 nm and a width of 14 to 22 nm, which is impregnated with collagen fibers at a weight ratio of said collagen fibers to said porous biphasic calcium phosphate/hydroxyapatite (CAP/HAP) bone substitute material of at least 2%,—a process of preparing the above porous CAP/HAP bone substitute material, which comprises (a) mixing a slurry of collagen fibers and a porous biphasic calcium phosphate/hydroxyapatite (CAP/HAP) bone substitute material comprising a sintered CAP core and at least one uniform and closed epitactically grown layer of nanocrystalline HAP deposited on top of the sintered CAP core, whereby the epitactically grown nanocrystals have the same size and morphology as human bone mineral, i.e. a length of 30 to 46 nm and a width of 14 to 22 nm, and (b) eliminating the water by vacuum suction, —an implant which comprises a porous collagen matrix surrounding and impregnating particles or granules of porous biphasic calcium phosphate/hydroxyapatite (CAP/HAP) bone substitute material comprising a sintered CAP core and at least one uniform and closed epitactically grown layer of nanocrystalline HAP deposited on top of the sintered CAP core, whereby the epitactically grown nanocrystals have the same size and morphology as human bone mineral, i.e. a length of 30 to 46 nm and a width of 14 to 22 nm, —the use of the above bone substitute material as implant or pros thesis for bone formation, bone regeneration, bone repair and/or bone replacement at a defect site in a human or animal.

METHOD FOR THE REALISATION OF A BIOMATERIAL COMPRISING CALCIUM PHOSPHATE SHAPED AS GRANULES AND/OR THEIR AGGLOMERATES AND BIOMATERIAL OBTAINED WITH THIS METHOD

Method for the realization of a calcium phosphate-based biomaterial in form of granules and/or agglomerates of re-absorbable granules which can be used in the biomedical industry as, e.g., bone fillers, for increasing the bone mass, as a sealing for the internal orthopaedic prosthesis, for releasing drugs and/or medicaments and/or other substances beneficial for the organism. A calcium phosphate-based biomaterial in form of granules and/or aggregates thereof obtained according to such method. 1. Method for the realization of a calcium phosphate-based biomaterial in form of re-absorbable granules and/or agglomerates of re-absorbable granules comprising the following steps:providing at least one calcium phosphate-based ceramic powder,providing at least one aqueous solution comprising a natural polysaccharide dissolved in said aqueous solution,preparing at least one ceramic suspension obtained by mixing said ceramic powder in said aqueous solution,extruding said at least one ceramic suspension in at least one laminar flow,fragmenting said at least one laminar flow of said at least one ceramic suspension into droplets, through means which determine a physical perturbation or through any other process suitable for the purpose, obtaining said droplets formed by said at least one ceramic suspension,{'b': '36', 'submerging—by dropping—said droplets () of said at least one ceramic suspension in a cross-linking solution,'}maintaining said droplets in said cross-linking solution with ensuing consolidation and jellification of said natural polysaccharide, contained in said ceramic suspension, in said cross-linking solution obtaining a jellified polysaccharide and acquisition of a conformation of particles by said droplets,washing said particles in water or any other liquid suitable for eliminating the excess of material and possible impurities;drying said particles with manual or automated separation of said particles, so as to avoid the contact therebetween, obtaining said ...

BIODEGRADABLE IMPLANT AND METHOD FOR MANUFACTURING SAME

This invention relates to a biodegradable implant including magnesium, wherein the magnesium contains, as impurities, (i) manganese (Mn); and (ii) one selected from the group consisting of iron (Fe), nickel (Ni) and mixtures of iron (Fe) and nickel (Ni), wherein the impurities satisfy the following condition: 0 Подробнее

COMPOSITIONS AND METHODS FOR TREATING THE VERTEBRAL COLUMN

The present invention relates to compositions and methods useful for treating structures of the vertebral column, including vertebral bodies. In one embodiment, a method for promoting bone formation in a vertebral body comprising providing a composition comprising a PDGF solution and a biocompatible matrix and applying the composition to at least one vertebral body. Promoting bone formation in a vertebral body, according to some embodiments, can increase bone volume, mass, and/or density leading to an increase in mechanical strength of the vertebral body treated with a composition of the present invention. 1. A method of preventing or inhibiting vertebral compression fractures comprising:providing a composition comprising a PDGF solution disposed in a biocompatible matrix; and,applying the composition to at least one vertebral body.2. The method of claim 1 , wherein applying comprises injecting the at least one vertebral body with the composition.3. The method of claim 1 , wherein the at least one vertebral body comprises a high risk vertebral body.4. A method for promoting or accelerating bone formation in a vertebral body comprising:providing a composition comprising a PDGF solution disposed in a biocompatible matrix; and,applying the composition to at least one vertebral body.5. The method of claim 4 , further comprising providing at least one pharmaceutical composition; and claim 4 ,administering the pharmaceutical composition locally to a patient.6. The method of claim 5 , wherein administering the pharmaceutical composition locally comprises disposing the pharmaceutical composition in or around the at least one vertebral body.7. The method of claim 4 , further comprising providing at least one pharmaceutical composition; and claim 4 ,administering the pharmaceutical composition systemically to a patient.8. The method of claim 7 , wherein administering the pharmaceutical composition systemically comprises oral administration claim 7 , intravenous administration ...

METHOD OF MANUFACTURING COMPOSITE MATERIAL SHAPED ARTICLE CONTAINING ACICULAR HYDROXYAPATITE, AND COMPOSITE MATERIAL SHAPED ARTICLE

A manufacturing method is a method of manufacturing a composite material molded article containing acicular hydroxyapatite. This manufacturing method comprises: a preparation step of mixing at least a calcium phosphate compound including α-tricalcium phosphate, a calcium compound containing no phosphorus, cellulose nanofibers, and an aqueous solvent consisting of water and/or a hydrophilic solvent to obtain a mixture; a molding step of forming a molded article by using the mixture; a drying step of drying the molded article; and a synthesis step of performing synthesis treatment of the molded article after drying. 1. A method of manufacturing a composite material molded article containing acicular hydroxyapatite , comprising:a preparation step of mixing at least a calcium phosphate compound including α-tricalcium phosphate, a calcium compound containing no phosphorus, cellulose nanofibers, and an aqueous solvent consisting of water and/or a hydrophilic solvent to obtain a mixture;a molding step of forming a molded article using the mixture;a drying step of drying the molded article; anda synthesis step of subjecting the molded article after drying to synthesis treatment.2. The method of manufacturing a composite material molded article containing acicular hydroxyapatite according to claim 1 , wherein in the preparation step claim 1 , the calcium compound is added so that a Ca/P ratio of the mixture is more than 1.50 and 1.80 or less.3. The method of manufacturing a composite material molded article containing acicular hydroxyapatite according to claim 1 , wherein in the preparation step claim 1 , the cellulose nanofibers are added at 10 to 40 parts by mass with respect to 100 parts by mass of the calcium phosphate compound.4. The method of manufacturing a composite material molded article containing acicular hydroxyapatite according to claim 1 , comprising claim 1 , before the molding step:a removal step of removing part or all of the aqueous solvent from the ...

BIOACTIVE POROUS BONE GRAFT IMPLANTS

Bioactive porous bone graft implants in various forms suitable for bone tissue regeneration and/or repair, as well as methods of use, are provided. The implants are formed of bioactive glass and have an engineered porosity. The implants may take the form of a putty, foam, fibrous cluster, fibrous matrix, granular matrix, or combinations thereof and allow for enhanced clinical results as well as ease of handling. 1. A bone graft implant , comprising:a first component comprising a bioactive glass material in the form of a plurality of glass fibers; anda second component comprising a bioactive glass material in the form of a bioactive glass crust at least partially covering the plurality of fibers;each of the first and second components having a different resorption capacity than the other component; anda third component comprising a biological agent;wherein the implant comprises a pore size distribution including pores characterized by pore diameters ranging from about 100 nanometers to about 1 millimeter.2. The implant of claim 1 , wherein at least one of the first and second components is partially or fully sintered.3. The implant of claim 1 , wherein at least one of the first and second components is porous.4. The implant of claim 1 , wherein the first component further comprises bioactive glass granules.5. The implant of claim 4 , wherein the bioactive glass crust extends over all of the plurality of fibers and granules.6. The implant of claim 1 , wherein the biological agent is selected from the group consisting of stem cells claim 1 , demineralized bone matrix claim 1 , bone marrow and platelet rich plasma.7. The implant of claim 1 , wherein the biological agent is selected from the group consisting of bone morphogenic protein claim 1 , a bone growth factor claim 1 , vascular endothelial growth factor claim 1 , insulin derived growth factor claim 1 , a keratinocyte derived growth factor claim 1 , and a fibroblast derived growth factor.8. The implant of claim 1 , ...

Method for Nano-Structuring Polmer Materials Using Pulsed Laser Radiation in an Inert Atmosphere

In a method for generating a surface having a solid polymeric material, which has surface structures with dimensions in the sub-micrometer range, the untreated surface, on which the structures are to be generated and which are accessible to laser radiation, is scanned once or multiple times using a pulsed laser beam in an inert gas atmosphere in such a way that adjacent light spots of the laser beam adjoin each other in a gapless manner or overlap and a certain range of a specified relation between process parameters is observed.

Implants having a high drug load of an oxysterol and methods of use

Provided is an implant configured to fit at or near a bone defect to promote bone growth, the implant comprising: a biodegradable polymer in an amount of about 0.1 wt % to about 20 wt % of the implant and an oxysterol in an amount of about 20 wt % to about 90 wt % of the implant. The implant has a high oxysterol load. Methods of making and use are further provided.

CURABLE CALCIUM PHOSPHATE COMPOSITIONS FOR USE WITH POROUS STRUCTURES AND METHODS OF USING THE SAME

Various embodiments disclosed relate to curable calcium phosphate compositions for use with porous structures and methods of using the same. In various embodiments, the present invention provides a curable calcium phosphate composition or a cured product thereof, with the curable calcium phosphate composition including calcium phosphate and a perfusion modifier. In various embodiments, the present invention provides an apparatus comprising a porous structure at least partially in contact with the curable calcium phosphate composition or a cured product thereof. The porous structure can include a porous substrate including a plurality of ligaments that define pores of the porous substrate, and a biocompatible metal coating on the plurality of ligaments of the porous substrate. 1. A curable calcium phosphate composition or a cured product thereof , the curable calcium phosphate composition comprising:calcium phosphate;a perfusion modifier, wherein the perfusion modifier is 0.5 wt % to 5 wt % of the curable calcium phosphate composition, wherein the perfusion modifier is methylcellulose, carboxymethylcellulose, hydroxypropylmethylcellulose, hydroxyethylcellulose, a salt thereof, or a combination thereof; anda physiologically acceptable fluid.2. The curable calcium phosphate composition or cured product thereof of claim 1 , wherein the physiologically acceptable fluid comprises water claim 1 , saline claim 1 , phosphate buffer claim 1 , biological fluid claim 1 , or a combination thereof claim 1 , and the biological fluid comprises blood claim 1 , a blood component claim 1 , a blood product claim 1 , milk claim 1 , urine claim 1 , saliva claim 1 , seminal fluid claim 1 , vaginal fluid claim 1 , synovial fluid claim 1 , lymph fluid claim 1 , amniotic fluid claim 1 , the fluid within a yolk sac of an egg claim 1 , chorion of an egg claim 1 , allantois of an egg claim 1 , sweat claim 1 , tears claim 1 , or a combination thereof.3. The curable calcium phosphate composition ...

THERMOPLASTIC MATERIALS INCORPORATING BIOACTIVE INORGANIC ADDITIVES

Composite materials comprising thermoplastic polymeric material such as polyaryletherketones (PAEKs) and inorganic additive species serving to increase the processing and resultant mechanical, thermal, and biological properties of said thermoplastic polymeric material which may be subsequently used in various medical applications after the two materials are mixed through thermal processing methods. The inorganic additive species may be a calcium salt, and may include fluorine ions. 1. An orthopaedic , bioactive composition with enhanced flowability and enhanced ductility , comprising a composite comprising:a. a high-viscosity, biocompatible polymeric matrix; andb. a homogenously distributed additive.wherein said polymeric matrix comprises a polyaryletherketone (PAEK), more preferably polyetheretherketone (PEEK), and wherein said additive comprises an additive species for improved melt-processability, article mechanical properties, and biological activity.2. The composition of claim 1 , wherein said polymeric matrix comprises a powder before processing and comprises an average diameter of between about 5 μm to about 2 claim 1 ,500 μm claim 1 , more preferably 10 μm to about 1 claim 1 ,000 μm claim 1 , most preferably 50 μm to about 500 μm.3. The composition of claim 2 , wherein said powder has a density of about 1.15 g/cm3 to about 1.5 g/cm3.4. The composition of claim 1 , wherein said polymeric material has a melt volume flow rate (MVR) of about 13 cm/10 min to about 15 cm/10 min at 400° C. and 5 kg of mass.5. The composition of claim 1 , wherein said polymeric matrix has an elongation to failure of about 55% to about 70%.6. The composition of claim 1 , wherein said additive acts as a flowing-aid.7. The composition of claim 1 , wherein said additive comprises a particulate with an average particulate size of between 0.2 μm to 1.5 μm claim 1 , more preferably 0.35 μm to 1.2 μm claim 1 , most preferably 0.5 μ to 1.0 μm.8. The composition of claim 1 , wherein said ...

Implanted Device

Disclosed is an implanted device, comprising a device base body and an active drug, wherein the device base body is pure zinc and/or a zinc alloy, the zinc content in the device base body is 0.1-100%, and the active drug comprises anti-allergic drugs. After the implantation of the implanted device into the human body, the surrounding tissues of the implant would not have a clear hypersensitive reaction due to the presence of the anti-allergic drugs, and the implanted device can be used to be implanted into the body for supporting organ chambers, to fill the hollow chambers of the organs and tissues or as orthopaedic implants etc. 1. An implanted device , comprising a device substrate and an active drug , wherein the device substrate is pure zinc and/or a zinc alloy; the device substrate contains 0.1 to 100 percent of zinc; and the active drug comprises an anti-allergic drug.2. The implanted device according to claim 1 , wherein the implanted device further comprises a zinc complexing agent; wherein the zinc complexing agent and the pure zinc or the zinc alloy in the device substrate form a complex in body fluid.3. The implanted device according to claim 2 , wherein the zinc complexing agent contains at least one coordination group; the coordination group is selected from the group consisting of hydroxyl on polycyclic aromatic hydrocarbon claim 2 , sulfydryl claim 2 , amino claim 2 , an aromatic heterocyclic group claim 2 , nitroso claim 2 , carbonyl claim 2 , sulpho claim 2 , a phosphate group and an organic phosphorus group; the hydroxyl on the polycyclic aromatic hydrocarbon is a phenolic hydroxyl; and the aromatic heterocyclic group is selected from the group consisting of furyl claim 2 , pyrryl claim 2 , imidazolyl claim 2 , triazolyl claim 2 , thienyl claim 2 , thiazolyl claim 2 , pyridyl claim 2 , a pyridone group claim 2 , pyranyl claim 2 , a pyrone group claim 2 , pyrimidyl claim 2 , pyridazinyl claim 2 , pyrazinyl claim 2 , quinolyl claim 2 , isoquinolyl ...

Platelet-Derived Growth Factor Compositions and Methods of Use Thereof

A method for promoting growth of bone, periodontium, ligament, or cartilage in a mammal by applying to the bone, periodontium, ligament, or cartilage a composition comprising platelet-derived growth factor at a concentration in the range of about 0.1 mg/mL to about 1.0 mg/mL in a pharmaceutically acceptable liquid carrier and a pharmaceutically-acceptable solid carrier.

Injectable Biodegradable Bone Matrix for Multiple Myeloma Lesion Augmentation and Osteoporosis

Bone filler compositions, methods of making and using the same, and methods of treating osteoporosis and cancer-induced bone defects, are described.

BONE REPAIR MATERIAL

Sliceable bone repair material is a porous block-shaped scaffold containing a hydrogel, wherein the hydrogel is formed by Michael type addition of at least two precursor molecules. Said scaffold is made of a synthetic ceramic material and has interconnected macropores having a diameter above 100 μm. In addition said scaffold has a total porosity of 80 to 95%. The total volume of the hydrogel is smaller than the total volume of the interconnected macropores. 1. A sliceable bone repair material comprising a porous block-shaped scaffold containing a hydrogel , wherein the hydrogel is formed by Michael type addition of at least two precursor molecules , and wherein said scaffold is made of a synthetic ceramic material and comprises interconnected macropores having a diameter above 100 μm , said scaffold having a total porosity of 80 to 95% , and the total volume of the hydrogel is smaller than the total volume of the interconnected macropores.2. Bone repair material according to claim 1 , wherein the hydrogel is a reconstituted hydrogel of a xerogel.3. Bone repair material according to claim 1 , wherein the hydrogel has a water content of more than 90% by weight.4. Bone repair material according to claim 1 , wherein 30 to 60 of the total volume of the interconnected macropores is filled with said hydrogel.5. Bone repair material according to claim 1 , wherein the hydrogel has a pH from 8.0 to 9.5.6. Bone repair material according to claim 1 , wherein the first precursor molecule has a core with 2 to 4 polyethylene glycol chains claim 1 , each chain having a terminal acrylate group.7. Bone repair material according to claim 1 , wherein the second precursor molecule has a core with 2 to 4 polyethylene glycol chains claim 1 , each chain having a thiol group which is terminal or attached to the second to last carbon atom.8. Bone repair material according to further comprising a bioactive agent.9. Bone repair material according to claim 8 , wherein the bioactive agent is ...

CALCIUM SULPHATE BASED COMPOSITE

A composite comprising monetite and calcium sulphate is provided. 1. A composite comprising monetite and calcium sulphate.2. The composite of claim 1 , wherein the monetite is in the form of granules in a matrix of calcium sulphate.3. The composite of claim 2 , where the granules range from about 10 to about 1500 μm in size.4. The composite of claim 2 , comprising between about 10 and about 80 wt % of granules claim 2 , based on the total dry weight of the composite.5. The composite of claim 1 , further comprising an accelerant.6. The composite of claim 5 , wherein the accelerant comprises seeds of calcium sulphate.7. The composite claim 1 , wherein the calcium sulphate is calcium sulphate hemihydrate in powder form claim 1 , and forms a powder matrix around the monetite.8. The composite claim 1 , wherein the calcium sulphate is calcium sulphate dihydrate or dehydrate in the form of a porous solid and forms a solid matrix around the monetite.9. The composite claim 1 , wherein the calcium sulphate is in powder form and wherein the calcium sulphate and the monetite are mixed with a curing liquid to form of a paste.10. The composite of claim 9 , wherein paste comprises between about 1.5 and about 4.0 g of calcium sulfate/monetite per ml of curing liquid.11. The composite of claim 10 , where the paste comprises between about 3.0 and about 4.0 g of calcium sulfate/monetite per ml of curing liquid12. The composite of claim 10 , wherein the curing liquid is saline or another non-toxic aqueous liquid.13. A bone graft substitute made of the composite of .14. A method for stimulating bone growth in a bone defect claim 1 , the method comprising:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'i. providing a composite according to ,'}ii. when needed, mixing the composite with a sterile curing liquid to form a paste,iii. applying the composite in or near the defect, andiv. when needed, allowing the composite to set.15. A method for stimulating bone growth in a gap between a ...

COMPOUNDS AND MATRICES FOR USE IN BONE GROWTH AND REPAIR

Compositions of small molecules, matrices, and isolated cells including methods of preparation, and methods for differentiation, transdifferentiation, and proliferation of animal cells into the osteoblast blast cell lineage were described. Examples of osteogenic materials that were administered to cells or co-cultured with cells are represented by compounds of Formula II, IV, and VI independently or preferably in combination with a matrix to afford bone cells. Small molecule-stimulated cells were also combined with a matrix, placed with a cellular adhesive or material carrier and implanted to a site in an animal for bone repair. Matrix pretreated with compounds of Formula II, IV, and VI were also used to cause cells to migrate to the matrix that is of use for therapeutic purposes. 1113. The composition of any one of - claims 1 , wherein the isolated cells capable of differentiating into bone cells are isolated human bone marrow-derived mesenchymal stem cells claims 1 , human mesenchymal stem cells of adipose tissue claims 1 , human mesenchymal stem cells of blood claims 1 , human mesenchymal stem cells of bone allograft or autograft tissues claims 1 , human mesenchymal stem cells of dental pulp claims 1 , human pericytes claims 1 , human myoblasts claims 1 , and human chondrocytes claims 1 , human osteoprogenitor cells claims 1 , urine stem cells claims 1 , or their respective progenitor cells such as stem cell isolated from amniotic fluid or cord blood claims 1 , embryonic stem cells claims 1 , and induced pluripotent stem cells.123. The composition of - wherein the calcium phosphate matrix is a tricalcium phosphate ceramic or is oseoinductive.137. The composition of - wherein the calcium phosphate matrix is a tricalcium phosphate ceramic or is oseoinductive.14. The composition of compound 8-10 wherein the calcium phosphate matrix is a tricalcium phosphate ceramic or is oseoinductive.1510. The compositions of any one of - further comprising a calcium phosphate ...

HIGHLY LOADED METAL OXIDE MATERIALS BY SELF-ASSEMBLY FOR EXTENDED BIOLOGICALLY ACTIVE MOLECULE RELEASE IN MEDICAL AND DENTAL APPLICATIONS

A biocompatible composite material for controlled release is disclosed, comprising a biocompatible metal oxide structure with a loaded network of pores. The pore network of the biocompatible composite material is filled with a uniformly distributed biologically active micellizing amphiphilic molecule, the size of these pores ranging from about 0.5 to about 100 nanometers. The material is characterized in that when exposed to phosphate-buffered saline (PBS), the controlled release of the active amphiphilic molecule is predominantly diffusion-driven over time. 1. A biocompatible composite material for controlled release , comprising:a biocompatible metal oxide structure containing a network of pores, said pores containing a biologically active agent, wherein the biologically active agent has a biocompatibility index of greater than 1, and wherein the active agent has amphiphilic characteristics resulting in micellization when placed in aqueous conditions.2. The composite material of claim 1 , wherein the biologically active agent is a pharmaceutical drug claim 1 , a pharmaceutical conjugated drug claim 1 , a pharmaceutical prodrug claim 1 , an antimicrobial claim 1 , an antiseptic agent claim 1 , an antifungal agent claim 1 , a peptide claim 1 , DNA or combinations thereof.3. The composite material of claim 1 , wherein the biologically active agent is an antimicrobial agent.4. The composite material of claim 1 , wherein the biologically active agent is any one of octenidine dihydrochloride claim 1 , polyhexamethylene biguanide claim 1 , cetylpyridinium chloride or lauric arginate.5. The composite material of wherein the biologically active agent comprises octenidine or a salt thereof.6. The composite material of having a controlled release of the biologically active agent from the composite material in phosphate-buffered saline (PBS) claim 1 , wherein the rate of release is predominantly driven by the diffusion of the biologically active agent out of the metal oxide ...

POROUS COMPOSITE AND BONE REGENERATION MATERIAL

[Problem to be Solved] To provide a porous composite that has excellent uniform dispersability of OCP and that comprises OCP and collagen in a sufficiently mixed state; and a bone regeneration material comprising the porous composite. [Means for Solution] A porous composite comprising octacalcium phosphate and collagen, characterized in that in an image obtained by enlarging a 5.0-mm×5.0-mm range of a plane of the porous composite 15 times with a scanning electron microscope (SEM), agglomerated particles of octacalcium phosphate have a fractal dimension (D) of 0.70 or more; and the area of c) portions consisting of collagen accounts for 5% or less of the total area of a) portions consisting of agglomerated particles of octacalcium phosphate, b) portions consisting of octacalcium phosphate microparticles and collagen, and the c) portions consisting of collagen. 1. A porous composite comprising octacalcium phosphate and collagen , characterized in thatin an image obtained by enlarging a 5.0-mm×5.0-mm range of a plane of the porous composite 15 times with a scanning electron microscope (SEM), agglomerated particles of octacalcium phosphate have a fractal dimension (D) of 0.70 or more; andthe area of (c) portions consisting of collagen accounts for 5% or less of the total area of (a) portions consisting of agglomerated particles of octacalcium phosphate, (b) portions consisting of octacalcium phosphate microparticles and collagen, and the (c) portions consisting of collagen.2. A porous composite comprising octacalcium phosphate and collagen , characterized in thatin an image obtained by enlarging a 5.0-mm×5.0-mm range of a plane of the porous composite 15 times with a scanning electron microscope (SEM), agglomerated particles of octacalcium phosphate have a fractal dimension (D) of 0.60 or more;the area of agglomerated particles of octacalcium phosphate having a length of 300 μm or more accounts for 75% or more of the total area of the agglomerated particles of ...

METHODS OF USING WATER-SOLUBLE INORGANIC COMPOUNDS FOR IMPLANTS

A method for controlling generation of biologically desirable voids in a composition placed in proximity to bone or other tissue in a patient by selecting at least one water-soluble inorganic material having a desired particle size and solubility, and mixing the water-soluble inorganic material with at least one poorly-water-soluble or biodegradable matrix material. The matrix material, after it is mixed with the water-soluble inorganic material, is placed into the patient in proximity to tissue so that the water-soluble inorganic material dissolves at a predetermined rate to generate biologically desirable voids in the matrix material into which bone or other tissue can then grow. 1162-. (canceled)163. An implant suitable for placement in a patient , comprising:an implant component having an outer surface;a poorly-water-soluble matrix material having a physically continuous interconnected matrix as a porous structure disposed on at least a portion of the outer surface of the implant component and defining interstices within the porous structure; andwater-soluble inorganic material blended within and attached within at least some of the interstices of the porous structure such that, when the implant is placed in proximity of tissue, the water-soluble inorganic material dissolves at a predetermined rate to generate biological desirable voids within said interstices into which tissue can grow to assist fixation of the implant within the patient.164. The implant according to wherein the poorly-water-soluble implant material includes metallic claim 163 , ceramic claim 163 , or polymeric material.165. The implant according to wherein the implant is a fixation device selected from the group including an external fixator pin claim 163 , a bone screw claim 163 , an artificial joint or an interbody spinal fusion device.166. The implant according to wherein the ceramic material includes at least one of hydroxyapatite claim 164 , tricalcium phosphate or biphasic calcium ...

Ceramic Part Having At Least One Ceramic Foam for Medical Applications

The invention relates to the use of ceramic parts that at least partly consist of a ceramic foam in the field of medical technology. 1. Ceramic part for medical applications which consists of a porous region and optionally a dense region , wherein the porous region consists of a ceramic foam being formed by an oxide-ceramic material or a non-oxide-ceramic material.2. Ceramic part for medical applications according to claim 1 , wherein the ceramic foam is selected from the AlO—ZrOmixed-oxide system or ceramic composite materials in which zirconia constitutes the volume-dominant phase.3. Ceramic part for medical applications according to claim 1 , wherein a pore size of the porous region is between a few 10 μm and 1 mm.4. Ceramic part for medical applications according to claim 1 , wherein the porous region has a porosity of from 20 to 95%.5. Ceramic part for medical applications according to claim 1 , wherein the ceramic part is an implant.6. Ceramic part for medical applications according to claim 5 , wherein fastening means can be inserted into the porous region of the implant.7. Ceramic part for medical applications according to claim 6 , wherein the fastening means include screws claim 6 , pins claim 6 , and nails.8. Ceramic part for medical applications according to claim 6 , wherein the fastening means have a diameter of up to 5 mm.9. Ceramic part for medical applications according to claim 5 , wherein the porous region can be machined.10. Ceramic part for medical applications according to claim 9 , wherein the machining is carried out by grinding and/or drilling and/or nailing and/or screwing and/or pressing.11. Ceramic part for medical applications according to claim 1 , wherein the porous region can be connected to a non-ceramic material.12. Ceramic part for medical applications according to claim 11 , wherein the porous region and the non-ceramic material are connected by plastics infiltration and/or by bonding.13. Use of the ceramic part according to for ...

INTRAOPERATIVE USES OF SETTABLE SURGICAL COMPOSITIONS

Provided herein are settable surgical compositions and methods for their intraoperative use. 1. A method for spinal fusion , the method comprising intraoperatively mixing two or more individual reactive putties to form an HPC , optionally dividing the HPC into two or more additional portions , and inserting a first portion of the HPC into an intervertebral space to form a spacer or cage.2. The method of claim 1 , further comprising introducing one or more of an autograft material claim 1 , an allograft material claim 1 , or a bone substitute material into one or more holes drilled into the HPC spacer or cage.3. The method of claim 1 , further comprising applying a second portion of the HPC to two or more spinal pedicles adjacent to the HPC spacer or cage to form two or more HPC anchor points on the pedicles and either stretching a further additional portion of the HPC between the anchor points or positioning a rod between the anchor points and pressing the rod into the anchor points claim 1 , thereby connecting the anchor points.4. A method for stabilizing surgical hardware claim 1 , the method comprising intraoperatively mixing two or more individual reactive putties to form an HPC optionally dividing the HPC into two or more additional portions claim 1 , and applying a first portion of the HPC between the surface of a bone and the joint hardware claim 1 , applying a second portion of the HPC across the surface of the joint hardware after it has been affixed to the bone claim 1 , or applying a first portion of the HPC between the surface of a bone and the joint hardware and applying a second portion of the HPC across the surface of the joint hardware after it has been affixed to the bone.5. A method for stabilizing a surgical screw claim 1 , the method comprising intraoperatively mixing two or more individual reactive putties to form an HPC claim 1 , filling a drilled or tapped hole with a portion of the HPC claim 1 , and inserting the screw into the HPC before it ...

Rollable bone implant for enclosing bone material

A bone implant for enclosing bone material is provided. The bone implant comprises a covering, which can be a biodegradable mesh. The covering is configured to be rolled into a diameter to at least partially enclose the bone material within the covering. In some embodiments, the covering includes a body portion and a closure portion adjacent to the body portion. The closure portion is configured to hold the covering in a rolled configuration to a predetermined diameter to at least partially enclose the bone material. A kit and a method of using the bone implant are also provided.

FABRICATING A CARBON NANOFIBER YARN NERVE SCAFFOLD

A carbo nanofiber nerve scaffold includes a cylindrical helix, a bundle of aligned carbon nanofiber yarns, and a carbon nanofiber sheet. The cylindrical helix includes a surgical suture material, and the cylindrical helix defines an interior of the carbon nanofiber nerve scaffold. The bundle of aligned carbon nanofiber yarns is disposed within the interior of the cylindrical helix. The carbon nanofiber sheet is disposed around the cylindrical helix on a side of the cylindrical helix opposite of the interior. 1. A carbon nanofiber nerve scaffold comprising:a cylindrical helix comprising a surgical suture material, the cylindrical helix defining an interior;a bundle of aligned carbon nanofiber yarns within the interior of the cylindrical helix; anda carbon nanofiber sheet around the cylindrical helix on a side of the cylindrical helix opposite the interior.2. The carbon nanofiber nerve scaffold of claim 1 , wherein the aligned segments of the bundle are spaced from 5 μm to 15 μm from one another.3. The carbon nanofiber nerve scaffold of claim 1 , wherein the carbon nanofiber sheet includes a bioresorbable polymer infiltrant.4. The carbon nanofiber nerve scaffold of claim 1 , wherein the cylindrical helix comprises a first helix wrapped in a first direction and a second helix wrapped in a second direction opposite the first helix.5. The carbon nanofiber nerve scaffold of claim 1 , wherein the cylindrical helix is a crocheted cylindrical helix.6. The carbon nanofiber nerve scaffold of claim 1 , wherein the cylindrical helix is a knitted cylindrical helix. This application is a Continuation of U.S. patent application Ser. No. 16/353,608, filed on Mar. 14, 2019, which claims priority to U.S. Provisional Patent Application No. 62/758,035, filed Nov. 9, 2018, and claims priority to U.S. Provisional Patent Application No. 62/643,496, filed Mar. 15, 2018. The disclosure of each of these documents, including the specification, drawings, and claims, is incorporated herein by ...

Implants having a drug load of an oxysterol and methods of use

Provided is a compression resistant implant configured to fit at or near a bone defect to promote bone growth. The compression resistant implant comprises a biodegradable polymer in an amount of about 0.1 wt % to about 20 wt % of the implant and a freeze-dried oxysterol in an amount of about 5 wt % to about 90 wt % of the implant. Methods of making and use are further provided.

TRICALCIUM PHOSPHATES, THEIR COMPOSITES, IMPLANTS INCORPORATING THEM, AND METHODS FOR THEIR PRODUCTION

Methods for the synthesis of tricalcium phosphates are presented, as well as a series of specific reaction parameters that can be adjusted to tailor, in specific ways, properties in the tricalcium phosphate precursor precipitate. Particulate tricalcium phosphate compositions having an average crystal size of about 250 nm or less are provided. Compositions of the invention can be used as prosthetic implants and coatings for prosthetic implants. 151-. (canceled)52. A composition comprising particulate tricalcium phosphate (TCP) having an average particle size of about 5 μm or less and an average crystal size of about 250 nm or less , wherein the particulate TCP comprises α-TCP.53. The composition of claim 52 , wherein the particulate TCP comprises pure α-TCP.54. The composition of claim 52 , wherein the particulate TCP has an average crystal size of about 200 nm or less.55. The composition of claim 52 , wherein the particulate TCP has an average crystal size of about 100 nm or less.56. The composition of claim 52 , wherein when the particulate TCP is densified to form an article having a minimum dimension of about 0.5 cm or greater the article transmits about 50% or more light having a wavelength in the range of about 150 nm to about 1 claim 52 ,000 nm.57. The composition of claim 56 , wherein when the particulate TCP is densified to form an article having a minimum dimension of about 0.5 cm or greater the article transmits about 70% or more light having a wavelength in the range of about 150 nm to about 1 claim 56 ,000 nm.58. The composition of claim 52 , wherein when the particulate TCP is densified to form an article having a minimum dimension of about 0.5 cm or greater the article has a compressive strength of 150 MPa or greater.59. The composition of claim 52 , wherein when the particulate TCP is densified to form an article having a minimum dimension of about 0.5 cm or greater the article has a density that is 90% of the theoretical density or greater.60. A ...

MIXED MATERIAL IMPLANTS INCORPORATING ADDITIVES

Disclosed are implants, devices and related manufacturing methods for implants comprising material mixtures including silicon nitride and/or other material additives in some of all of the implant body, including portions, layers and/or surface coatings thereof, for use as orthopedic implants such as joint and/or bone replacement implants used in in spinal surgeries, dental surgeries and/or other orthopedic procedures. 1. An interbody system for implanting between vertebrae , comprising:a cage having a cage body comprising at least one material from the group consisting of titanium, chrome cobalt, stainless steel, silicone, poly (ether ether ketone) (PEEK), ultra-high molecular-weight polyethylene (UHMWPE), polyurethane foam, polylactic acid and apatite, the cage body having at least one externally facing surface, anda dispersed particulate layer of silicon nitride at least partially disposed within the cage body.2. The interbody system of claim 1 , wherein at least a portion of the dispersed particulate layer of silicon nitride is exposed on the at least one externally facing surface of the cage body.3. The interbody system of claim 1 , wherein at least a portion of the dispersed particulate layer of silicon nitride is exposed on an internally facing surface of the cage body.4. The interbody system of claim 1 , wherein at least a portion of the dispersed particulate layer of silicon nitride is encased within the cage body.5. The interbody system of claim 1 , wherein the dispersed particulate layer of silicon nitride comprises a powdered silicon nitride particulate that is mixed with the at least one material prior to forming the cage body by injection molding.6. The interbody system of claim 1 , wherein the dispersed particulate layer of silicon nitride comprises a liquified silicon nitride particulate that is mixed with the at least one material prior to forming the cage body by injection molding.7. The interbody system of claim 1 , wherein the dispersed ...

Platelet-Derived Growth Factor Compositions and Methods of Use Thereof

A method for promoting growth of bone, periodontium, ligament, or cartilage in a mammal by applying to the bone, periodontium, ligament, or cartilage a composition comprising platelet-derived growth factor at a concentration in the range of about 0.1 mg/mL to about 1.0 mg/mL in a pharmaceutically acceptable liquid carrier and a pharmaceutically-acceptable solid carrier. 178-. (canceled)79. A method for promoting growth of bone , ligament , or cartilage of a mammal comprising administering to the mammal an implant material comprising a porous calcium phosphate having a solution of platelet-derived growth factor (PDGF) disposed therein , wherein:a) the PDGF has a concentration in a range of about 0.1 mg/mL to about 1.0 mg/mL;b) the calcium phosphate comprises: i) interconnected pores, ii) particles having a size ranging from about 100 microns to about 5000 microns, and iii) a porosity greater than 90%;c) the implant material does not comprise demineralized freeze dried bone allograft; andd) the implant material promotes the growth of the bone, ligament, or cartilage.80. The method of claim 79 , wherein the PDGF has a concentration of about 0.3 mg/mL.81. The method of claim 79 , wherein the PDGF has a concentration of about 1.0 mg/mL.82. The method of claim 79 , wherein the calcium phosphate comprises tricalcium phosphate claim 79 , hydroxyapatite claim 79 , poorly crystalline hydroxyapatite claim 79 , amorphous calcium phosphate claim 79 , calcium metaphosphate claim 79 , dicalcium phosphate dihydrate claim 79 , heptacalcium phosphate claim 79 , calcium pyrophosphate dihydrate claim 79 , calcium pyrophosphate claim 79 , octacalcium phosphate claim 79 , or any mixture thereof.83. The method of claim 79 , wherein the calcium phosphate comprises β-tricalcium phosphate (β-TCP).84. The method of claim 83 , wherein the β-TCP comprises particles having a size ranging from about 100 μm to about 3000 μm.85. The method of claim 84 , wherein the β-TCP comprises particles having ...

Porous implant structures

Porous biocompatible structures suitable for use as medical implants and methods for fabricating such structures are disclosed. The disclosed structures may be fabricated using rapid manufacturing techniques. The disclosed porous structures have a plurality of struts and nodes where no more than two struts intersect one another to form a node. Further, the nodes can be straight, curved, portions that are curved and/or portions that are straight. The struts and nodes can form cells which can be fused or sintered to at least one other cell to form a continuous reticulated structure for improved strength while providing the porosity needed for tissue and cell in-growth.

BIOACTIVE POROUS BONE GRAFT IMPLANTS

Bioactive porous bone graft implants in various forms suitable for bone tissue regeneration and/or repair, as well as methods of use, are provided. The implants are formed of bioactive glass and have an engineered porosity. The implants may take the form of a putty, foam, fibrous cluster, fibrous matrix, granular matrix, or combinations thereof and allow for enhanced clinical results as well as ease of handling. 1. A bone graft implant , comprising:a first component comprising a bioactive glass material in the form of a plurality of glass fibers; anda second component comprising a bioactive glass material in the form of a bioactive glass crust at least partially covering the plurality of fibers;each of the first and second components having a different resorption capacity than the other component; anda third component comprising a biological agent;wherein the implant comprises a pore size distribution including pores characterized by pore diameters ranging from about 100 nanometers to about 1 millimeter.2. The implant of claim 1 , wherein at least one of the first and second components is partially or fully sintered.3. The implant of claim 1 , wherein at least one of the first and second components is porous.4. The implant of claim 1 , wherein the first component further comprises bioactive glass granules.5. The implant of claim 4 , wherein the bioactive glass crust extends over all of the plurality of fibers and granules.6. The implant of claim 1 , wherein the biological agent is selected from the group consisting of stem cells claim 1 , demineralized bone matrix claim 1 , bone marrow and platelet rich plasma.7. The implant of claim 1 , wherein the biological agent is selected from the group consisting of bone morphogenic protein claim 1 , a bone growth factor claim 1 , vascular endothelial growth factor claim 1 , insulin derived growth factor claim 1 , a keratinocyte derived growth factor claim 1 , and a fibroblast derived growth factor.8. The implant of claim 1 , ...

Ceramic Sliding Bearing

Disclosed is a ceramic sliding partner for a sliding bearing, said sliding partner being made at least in part, preferably entirely, of a ceramic foam. The ceramic sliding partner comprises at least one sliding surface on which a sliding partner can move, said sliding surface being made at least in part, preferably entirely, of a ceramic foam.

Methods of Using Water-Soluble Inorganic Compounds for Implants

A method for controlling generation of biologically desirable voids in a composition placed in proximity to bone or other tissue in a patient by selecting at least one water-soluble inorganic material having a desired particle size and solubility, and mixing the water-soluble inorganic material with at least one poorly-water-soluble or biodegradable matrix material. The matrix material, after it is mixed with the water-soluble inorganic material, is placed into the patient in proximity to tissue so that the water-soluble inorganic material dissolves at a predetermined rate to generate biologically desirable voids in the matrix material into which bone or other tissue can then grow.

Solid forms for tissue repair

This invention provides aragonite- and calcite-based scaffolds for the repair, regeneration, enhancement of formation or a combination thereof of cartilage and/or bone, which scaffolds comprise at least two phases, wherein each phase differs in terms of its chemical content, or structure, kits comprising the same, processes for producing solid aragonite or calcite scaffolds and methods of use thereof.

Biodegradable Magnesium Alloys and Composites

Biodegradable, magnesium alloys and composites, articles produced therefrom, methods of making the same, and methods of using the same are described. 1. A composite comprising:magnesium;a rare earth element present at a concentration up to about 15 wt %; andsilica present at a concentration up to about 15 wt %;wherein the composite has a nanocrystalline grain size.2. (canceled)3. The composite of claim 1 , wherein the rare earth element is not present in an oxide.4. The composite of claim 3 , wherein the rare earth element is selected from the group consisting of yttrium (Y) claim 3 , gadolinium (Gd) claim 3 , terbium (Tb) claim 3 , dysprosium (Dy) claim 3 , neodymium (Nd) claim 3 , lanthanum (La) claim 3 , cerium (Ce) claim 3 , praseodymium (Pr) claim 3 , and samarium (Sm).5. (canceled)6. The composite of claim 1 , further comprising an additive selected from the group consisting of Ti claim 1 , Al claim 1 , Zr claim 1 , Zn claim 1 , and Mn.7. The composite of claim 1 , wherein the composite consists essentially of magnesium claim 1 , yttrium claim 1 , and silica.8. The composite of claim 1 , further comprising a Ca—P coating.9. The composite of claim 8 , wherein the Ca—P coating is selected from the group consisting of: hydroxyapatite (Ca(PO)(OH)) claim 8 , tetracalcium phosphate (TTCP claim 8 , Ca(PO)O) claim 8 , tricalcium phosphate [α-TCP claim 8 , α-Ca(PO)and β-TCP claim 8 , β-Ca(PO)] claim 8 , dicalcium phosphate anhydrous (DCPA claim 8 , monetite claim 8 , CaHPO) claim 8 , di-calcium phosphate dihydrate (DCPD claim 8 , brushite claim 8 , CaHPO.2HO) claim 8 , and octacalcium phosphate (OCP claim 8 , CaH(PO).5HO).10. (canceled)11. (canceled)12. (canceled)13. An article comprising the composite of claim 1 , wherein the article is selected from the group consisting of: orthopedic implants claim 1 , cochlear implants claim 1 , surgical staples claim 1 , aneurism coils claim 1 , vascular closing devices claim 1 , plates claim 1 , screws claim 1 , intramedullary ...

Platelet-Derived Growth Factor Compositions and Methods of Use Thereof

A method for promoting growth of bone, periodontium, ligament, or cartilage in a mammal by applying to the bone, periodontium, ligament, or cartilage a composition comprising platelet-derived growth factor at a concentration in the range of about 0.1 mg/mL to about 1.0 mg/mL in a pharmaceutically acceptable liquid carrier and a pharmaceutically-acceptable solid carrier. 178-. (canceled)79. An implant material comprising a porous calcium phosphate having incorporated therein a liquid comprising platelet derived growth factor (PDGF) at a concentration in a range of about 0.1 mg/mL to about 1.0 mg/mL in a buffer , wherein the calcium phosphate has interconnected pores , a porosity greater than 40% , and comprises particles in a range of about 100 microns to about 5000 microns in size.80. The implant material of claim 79 , wherein the PDGF is recombinant PDGF.81. The implant material of claim 79 , wherein the PDGF is recombinant PDGF-BB.82. The implant material of claim 79 , wherein the liquid comprises PDGF at a concentration of about 0.3 mg/mL in a buffer.83. The implant material of wherein the liquid comprises PDGF at a concentration in a range of about 0.25 mg/mL to about 0.5 mg/mL in a buffer.84. The implant material of wherein the calcium phosphate is tricalcium phosphate.85. The implant material of wherein the calcium phosphate comprises particles in a range of about 100 microns to about 3000 microns in size.86. The implant material of wherein the calcium phosphate comprises particles in a range of about 250 microns to about 1000 microns in size.87. The implant material of wherein the implant material is resorbable such that at least 80% of the calcium phosphate is resorbed within one year of being implanted.88. The implant material of wherein the incorporated liquid is adsorbed onto or absorbed by the calcium phosphate.89. An implant material comprising a calcium phosphate having incorporated therein a liquid comprising platelet derived growth factor (PDGF) at a ...

Platelet-Derived Growth Factor Compositions and Methods of Use Thereof

A method for promoting growth of bone, periodontium, ligament, or cartilage in a mammal by applying to the bone, periodontium, ligament, or cartilage a composition comprising platelet-derived growth factor at a concentration in the range of about 0.1 mg/mL to about 1.0 mg/mL in a pharmaceutically acceptable liquid carrier and a pharmaceutically-acceptable solid carrier. 178-. (canceled)79. An implant material comprising a porous calcium phosphate having incorporated therein a solution comprising a comprising platelet derived growth factor (PDGF) at a concentration in a range of about 0.1 mg/mL to about 1.0 mg/mL in a buffer , wherein the calcium phosphate has interconnected pores , a porosity greater than 40% , and comprises particles in a range of about 100 microns to about 5000 microns in size , and a biocompatible binder is a polymer selected from the group consisting of polysaccharides , nucleic acids , carbohydrates , proteins , polypeptides and mixtures thereof.80. The implant material of claim 79 , wherein the biocompatible binder is selected from the group consisting of poly(α-hydroxy acids) claim 79 , poly(lactones) claim 79 , poly(amino acids) claim 79 , poly(anhydrides) claim 79 , poly(orthoesters) claim 79 , poly(anhydride-co-imides) claim 79 , poly(orthocarbonates) claim 79 , poly(α-hydroxy alkanoates) claim 79 , poly(dioxanones) claim 79 , poly(phosphoesters) claim 79 , polylactic acid claim 79 , poly(L-lactide) (PLLA) claim 79 , poly(D claim 79 ,L-lactide) (PDLLA) claim 79 , polyglycolide (PGA) claim 79 , poly(lactide-co-glycolide (PLGA) claim 79 , poly(L-lactide-co-D claim 79 , L-lactide) claim 79 , poly(D claim 79 ,L-lactide-co-trimethylene carbonate) claim 79 , polyglycolic acid claim 79 , polyhydroxybutyrate (PHB) claim 79 , poly(ε-caprolactone) claim 79 , poly(δ-valerolactone) claim 79 , poly(γ-butyrolactone) claim 79 , poly(caprolactone) claim 79 , polyacrylic acid claim 79 , polycarboxylic acid claim 79 , poly(allylamine hydrochloride) claim 79 ...

SOLID FORMS FOR TISSUE REPAIR

This invention provides aragonite- and calcite-based scaffolds for the repair, regeneration, enhancement of formation or a combination thereof of cartilage and/or bone, which scaffolds comprise at least two phases, wherein each phase differs in terms of its chemical content, or structure, kits comprising the same, processes for producing solid aragonite or calcite scaffolds and methods of use thereof. 1. A scaffold for tissue repair; said scaffold consisting essentially of two phases wherein:a first phase of said two phases comprises solid coral or biolattice comprising a biocompatible polymer and said first phase further comprises a series of hollows along a longitudinal axis in said first phase, wherein said biocompatible polymer is substantially located within said series of hollows; anda second phase of said two phases comprises a solid coral or biolattice.2104.-. (canceled) Surgical intervention and grafting are sometimes necessary to restore mechanical function and reconstruct the morphology of bone and cartilage, resulting from trauma, tumors, or abnormal bone developments.Synthetic materials such as metals and bone cements have also been used for restoring and reconstructing bone for many years, but often result in stress-shielding to the surrounding bone and fatigue failure of the implant. Another possibility is autologous bone grafting, although the supply of autologous bone tissue is limited and its collection is painful, with the risk of infection, hemorrhage, cosmetic disability, nerve damage, and loss of bone function. In addition, significant morbidity is associated with autograft harvest sites. These problems may be overcome by engineering tissue using scaffolds made of synthetic or natural biomaterials that promote the adhesion, migration, proliferation, and differentiation of bone marrow stem cells, also known as mesenchymal stem cells (MSCs). An association between biocomponents and biologic regenerative and repair responses can be promoted by ...

ADDITIVE MANUFACTURING COMPONENTS AND METHODS

A method of 3D printing comprises: providing a layer of a powder bed; jetting a functional binder onto selected parts of said layer, wherein said binder infiltrates into pores in the powder bed and locally fuses particles of the powder bed in situ; sequentially repeating said steps of applying a layer of powder on top and selectively jetting functional binder, multiple times, to provide a powder bed bonded at selected locations by printed functional binder; and taking the resultant bound 3D structure out of the powder bed. 1. A method of 3D printing comprising:providing a layer of a powder bed;jetting a functional binder onto selected parts of said layer, wherein said binder infiltrates into pores in the powder bed and locally fuses particles of the powder bed in situ;sequentially repeating said steps of applying a layer of powder on top and selectively jetting functional binder, multiple times, to provide a powder bed bonded at selected locations by printed functional binder; andtaking the resultant bound 3D structure out of the powder bed.2. A method as claimed in further comprising a subsequent step of heat treatment either inter-layer or post-build to further fuse the 3D structure.3. A method as claimed in wherein the functional binder comprises a metallic binder.4. A method as claimed in wherein the metallic binder comprises an organometallic material.5. A method as claimed in wherein the organometallic material is a copper metal precursor claim 4 , for example comprising cyclopentadienyl and/or isocyanide ligands.6. A method as claimed in wherein the organometallic material is a nickel metal precursor claim 4 , for example nickel acetylacetonate.7. A method as claimed in wherein the organometallic material is a titanium metal precursor claim 4 , for example a titanium amide.8. A method as claimed in wherein the functional binder comprises a ceramic binder.9. A method as claimed in wherein the binder further comprises metallic or ceramic nanoparticles with ...

SILICA-BASED COMPOSITE OCULAR DEVICE AND METHODS

Disclosed herein are synthetic silica-based ocular devices fabricated from a composite material comprising silica and a fibrillar protein, together with methods of making and using the ocular devices. 110-. (canceled)11. A contact lens comprising a structure formed from an optically clear , biocompatible , composite comprising a silica component and a fibrillar component.12. The contact lens of wherein the fibrillar component is collagen.13. The contact lens of wherein the fibrillar component is soluble collagen.14. The contact lens of further comprising an osmolyte.15. The contact lens of further comprising a therapeutic agent.16. The contact lens of fabricated to protect the eye or promote healing of eye tissue.17. The contact lens of comprising a silica component/fibrillar component ratio of from 40:1 to 1:40.18. A method of using a contact lens as described herein.19. (canceled) This application claims the benefit of U.S. Provisional Application Ser. No. 61/302,362, filed Feb. 8, 2010, which is incorporated by reference herein in its entirety.The cornea is the most anterior portion of the eye and creates the interface between the eye and the external environment. Due to its location, the cornea acts as a barrier, shielding the inner eye from foreign debris. The cornea must also allow light to pass through to the lens and, ultimately, the retina. The cornea is responsible for a majority of the light refraction into the eye.The cornea is a highly ordered tissue. depicts the layers of the cornea: the epithelium, Bowman's layer, the stroma, Descemet's membrane, and the endothelium, from anterior to posterior. The epithelium is made up of six to eight layers of epithelial cells. The newest, youngest, cells are the most posterior and move up through the layers to the most anterior cornea. This makes the cells at the anterior cornea the oldest, and these are swept away in the tear film as they age (Oyster and Clyde, “The Cornea and the Sclera,” in Sinauer Associates, ...

BIODEGRADABLE COMPOSITE MATERIAL

The invention relates to a biologically degradable composite material and to a process for the preparation thereof. The biologically degradable composite material according to the invention is preferably a bone reconstruction material which can be used in the field of regenerative medicine, especially as a temporary bone defect filler for bone regeneration. 138-. (canceled)40. The biologically degradable composite material of claim 39 , wherein the first inorganic component (a) has a bulk density of approximately 0.8-1.5 g/cmand the second inorganic component (b) has a bulk density of approximately 0.5-0.9 g/cm claim 39 , with the proviso that the bulk density of the second inorganic component (b) is different than that of the first inorganic component (a) and the difference in density is at least 0.1 g/cm claim 39 , and wherein the bulk density of the second inorganic component (b) is less than that of the first inorganic component (a).41. The biologically degradable composite material of claim 39 , wherein the first inorganic component (a); or the second inorganic component (b); or the third inorganic component (d); the first inorganic component (a) claim 39 , and the second inorganic component (b) or the third inorganic component (d); or the first inorganic component (a) claim 39 , the second inorganic component (b) and the third inorganic component (d) contain(s) micropores claim 39 , mesopores claim 39 , macropores claim 39 , or a combination thereof claim 39 , wherein the micropores claim 39 , mesopores or macropores interconnect.42. The biologically degradable composite material of claim 41 , wherein the micropores form an interconnecting network into which discrete mesopores and macropores have been introduced in homogeneous distribution.43. The biologically degradable composite material of claim 39 , wherein the first inorganic component (a) claim 39 , the second inorganic component (b) claim 39 , and the third inorganic component (d) are in each case a ...

Particulate Materials And Compositions For Radio Therapy

Timed-bioresorbable particulates, particularly microspheres or fibers, may be used as a vehicle for delivery of radioisotopes, such as Y-90 and Pd-103 for localized radiotherapy, or as an embolic device. These particulates may also be embedded in polymers, or dispersed in injectable gels or other injectable media for the treatment of various cancers. The benefit of bioresorption, the ability to control the ratio of radioisotopes in the particulate, especially the gamma and beta ratios such as In-111/Y-90 ratio in a particulate, and the benefit of non-conductive implants are disclosed. 135-. (canceled)36. A suspension comprising a matrix suspended or dispersed in viscous medium , tissue adhesive medium , iodized medium , or gel medium , wherein said matrix comprises radioactive isotopes.37. The suspension of claim 36 , wherein said radioactive isotopes are Y-90 claim 36 , In-111 claim 36 , Pd-103 claim 36 , P-32 claim 36 , Cs-131 claim 36 , Sm-153 claim 36 , Ho-166 claim 36 , Tc-99m claim 36 , Yb-169 claim 36 , Au-198 claim 36 , Re-188 claim 36 , Re-186 claim 36 , Ir-192 claim 36 , Lu-177 claim 36 , Ba-140 claim 36 , Se-72 claim 36 , 1-131 claim 36 , 1-125 claim 36 , Sr-90 claim 36 , Dy-165 claim 36 , Er claim 36 , Tl claim 36 , Sr claim 36 , Gd claim 36 , Y-90/In-111 claim 36 , Y-90/Tc-99m claim 36 , P-32/In-111 claim 36 , P-32/Tc-99m claim 36 , Ho-166/In-111 claim 36 , Ho-166/Tc-99m claim 36 , Sm-153/In-111 claim 36 , Sm-153/Tc-99m claim 36 , or combinations thereof.38. The suspension of claim 36 , wherein said radioactive isotopes are present in an amount effective for radiation therapy of a tumor.39. The suspension of claim 36 , wherein said matrix is a particulate claim 36 , microsphere claim 36 , porous microsphere claim 36 , hollow microsphere claim 36 , microcapsule claim 36 , solid or porous fiber claim 36 , small solid or porous rod claim 36 , particulate dispersed in biopolymers claim 36 , particulate dispersed in bioresorbable sutures claim 36 , ...

BONE VOID FILLER HAVING CALCIUM COATINGS

A bone void filler material is provided for sustained release of a therapeutic agent. The bone void filler material comprising a biodegradable matrix having ceramic cement beads comprising calcium sulfate, and ceramic particles disposed within the matrix. The ceramic cement beads are loaded with the therapeutic agent to cause sustained release of the therapeutic agent. Methods of use are also disclosed. 1. A bone void filler material for sustained release of a therapeutic agent , the bone void filler material comprising a biodegradable matrix having ceramic cement beads comprising calcium sulfate , and ceramic particles disposed within the matrix , the ceramic cement beads being loaded with the therapeutic agent to cause sustained release of the therapeutic agent.2. A bone void filler material according to claim 1 , wherein the biodegradable matrix comprises collagen claim 1 , chitosan claim 1 , keratin claim 1 , alginate claim 1 , hyaluronic acid or a combination thereof.3. A bone void filler material according to claim 1 , wherein the biodegradable matrix comprises collagen claim 1 , and the collagen comprises human collagen type I claim 1 , human collagen type II claim 1 , human collagen type III claim 1 , human collagen type IV claim 1 , human collagen type V claim 1 , human collagen type VI claim 1 , human collagen type VII claim 1 , or a combination thereof.4. A bone void filler material according to claim 1 , wherein the ceramic particles are slow resorbing and comprise hydroxyapatite (HA) claim 1 , tricalcium phosphate (TCP) or a combination thereof.5. A bone void filler material according to claim 1 , wherein (i) the ceramic cement beads are settable; and (ii) the therapeutic agent is released from the ceramic cement beads in a sustained release over a period of at least 1 day to about 12 months.6. A bone void filler material according to claim 1 , wherein the ceramic cement beads are from about 1 micron to about 200 microns in size.7. A bone void filler ...

DYNAMIC BIOACTIVE BONE GRAFT MATERIAL HAVING AN ENGINEERED POROSITY

The present disclosure relates to a dynamic bioactive bone graft material having an engineered porosity. In one embodiment, a bone graft material is provided having bioactive glass fibers arranged in a porous matrix that is moldable into a desired shape for implantation. The material can be substantially without additives and can include at least one nanofiber. The porous matrix may include a combination of one or more pore sizes including nanopores, macropores, mesopores, and micropores. In another embodiment, a bone graft implant is provided having a matrix comprising a plurality of overlapping and interlocking bioactive glass fibers, and having a distributed porosity based on a range of pores provided in the bioactive glass fibers. The distributed porosity can comprise a combination of macropores, mesopores, and micropores, and the matrix can be formable into a desired shape for implantation into a patient. 1. A method of treating a bone defect , comprising:providing a bone graft material, the material comprising:a porous matrix comprising a plurality of overlapping and interlocking bioactive glass fibers and bioactive glass particulates distributed throughout the fibers, the fibers and particulates each having varying diameters, and a range of pores defined by the spaces between said fibers and particulates, the varying diameters of the fibers and particulates controlling pore size and distribution of the range of pores and overall porosity of the matrix, the matrix further having a distributed porosity based on said range of pores such that the matrix is configured for staged resorption, the range of pores comprising micropores and macropores;forming an implant from the bone graft material, the implant being formed by shaping the material into a shape and size for insertion into the bone defect; andimplanting the formed implant into the bone defect.2. The method of claim 1 , wherein the range of pores further comprises nanopores or mesopores.3. The method of ...

IMPLANT WITH INTRINSIC ANTIMICROBIAL EFFICACY, AND METHOD FOR THE PRODUCTION THEREOF

The invention relates to an implant () with antimicrobial activity, comprising an implant mixture (IM) which has a base granular material () formed from a raw material mixture of biocompatible polymers and/or a ceramic granular material, the implant mixture (IM) also comprising at least one type of metal () in particle form which is suitable for releasing ions, the metal particles () being present in the form of silver particles and/or copper particles. The metal particles () are distributed in the volume of the implant (). The invention also relates to a method for producing an implant () of said type. 1. An implant with antimicrobial activity comprising an implant mixture having a base granular material made of a raw material mixture of biocompatible polymers and/or a ceramic granular material , wherein the implant mixture further comprises at least one kind of particulate metal suitable for releasing ions , wherein the metal particles are provided in the form of silver particles and/or copper particles , wherein the metal particles are distributed in the volume of the implant so that the metal is interspersed with further metal particles in the form of magnesium particles and/or iron particles , which are highly pure and elemental as well as biodegradable metals.2. The implant according claim 1 , wherein the distribution claim 1 , density claim 1 , quantity and/or concentration of the metal particles in the implant mixture is such that the antimicrobial activity of the implant is forced to occur in its direct environment.3. The implant according to claim 1 , wherein the silver particles have a grain size in the range of 1-200 μm claim 1 , the copper particles have a grain size in the range of 1-100 μm claim 1 , and the magnesium particles and iron particles have a grain size in the range of 1-200 μm.4. The implant according to claim 1 , wherein the implant is porous in such a way that the antimicrobial activity of the porous implant is forced to occur on the pore ...

PLATELET-DERIVED GROWTH FACTOR COMPOSITIONS AND METHODS OF USE THEREOF

A method for promoting growth of bone, periodontium, ligament, or cartilage in a mammal by applying to the bone, periodontium, ligament, or cartilage a composition comprising platelet-derived growth factor at a concentration in the range of about 0.1 mg/mL to about 1.0 mg/mL in a pharmaceutically acceptable liquid carrier and a pharmaceutically-acceptable solid carrier. 178-. (canceled)79. An implant material comprising a porous calcium phosphate having incorporated therein a solution comprising platelet derived growth factor (PDGF) having a concentration ranging from about 0.1 mg/mL to about 1.0 mg/mL in a buffer , wherein the calcium phosphate comprises interconnected pores , a porosity greater than 40% , and particles having a size ranging from about 100 microns to about 5000 microns ,wherein the calcium phosphate is chosen from one or more of tricalcium phosphate, hydroxyapatite, amorphous calcium phosphate, calcium metaphosphate, dicalcium phosphate dihydrate, heptacalcium phosphate, calcium pyrophosphate dihydrate, calcium pyrophosphate, and octacalcium phosphate, andwherein the implant material does not comprise demineralized freeze-dried bone allograft.80. The implant material of claim 79 , wherein the PDGF comprises recombinant PDGF.81. The implant material of claim 79 , wherein the PDGF comprises recombinant human PDGF-BB.82. The implant material of claim 79 , wherein the solution comprises PDGF at a concentration of about 0.3 mg/mL.83. The implant material of claim 79 , wherein the solution comprises PDGF having a concentration ranging from about 0.25 mg/mL to about 0.5 mg/mL.84. The implant material of claim 79 , wherein the solution comprises PDGF having a concentration ranging from about 0.2 mg/mL to about 0.75 mg/mL.85. The implant material of claim 79 , wherein the calcium phosphate comprises particles having a size ranging from about 100 microns to about 3000 microns.86. The implant material of claim 79 , wherein the calcium phosphate comprises ...

COMPOUNDS AND MATRICES FOR USE IN BONE GROWTH AND REPAIR

Compositions of small molecules, matrices, and isolated cells including methods of preparation, and methods for differentiation, trans-differentiation, and proliferation of animal cells into the osteoblast cell lineage were described. Examples of osteogenic materials that were administered to cells or co-cultured with cells are represented by compounds of Formula II, IV, and VI independently or preferably in combination with a matrix to afford bone cells. Small molecule-stimulated cells were also combined with a matrix, placed with a cellular adhesive or material carrier and implanted to a site in an animal for bone repair. Matrix pretreated with compounds of Formula II, IV, and VI were also used to cause cells to migrate to the matrix that is of use for therapeutic purposes. 11. The composition of any one of - , wherein the isolated cells capable of differentiating into bone cells are isolated human bone marrow-derived mesenchymal stem cells , human mesenchymal stem cells of adipose tissue , human mesenchymal stem cells of blood , human mesenchymal stem cells of bone allograft or autograft tissues , human mesenchymal stem cells of dental pulp , human pericytes , human myoblasts , and human chondrocytes , human osteoprogenitor cells , urine stem cells , or their respective progenitor cells such as stem cell isolated from amniotic fluid or cord blood , embryonic stem cells , and induced pluripotent stem cells.12. The composition of - wherein the calcium phosphate matrix is a tricalcium phosphate ceramic or is oseoinductive.13. The composition of - wherein the calcium phosphate matrix is a tricalcium phosphate ceramic or is oseoinductive.14. The composition of compound 8-10 wherein the calcium phosphate matrix is a tricalcium phosphate ceramic or is oseoinductive.15. The compositions of any one of - further comprising a calcium phosphate matrix , wherein the compound is covalently associated onto the calcium phosphate matrix.16. The compositions of any one of - ...

BONE VOID FILLER HAVING CALCIUM COATINGS

A bone void filler material is provided for sustained release of a therapeutic agent. The bone void filler material comprising a biodegradable matrix having ceramic cement beads comprising calcium sulfate, and ceramic particles disposed within the matrix. The ceramic cement beads are loaded with the therapeutic agent to cause sustained release of the therapeutic agent. Methods of use are also disclosed. 1. A bone void filler material for sustained release of a therapeutic agent , the bone void filler material comprising a biodegradable matrix having ceramic cement beads comprising calcium sulfate , and ceramic particles disposed within the matrix , the ceramic cement beads being loaded with the therapeutic agent to cause sustained release of the therapeutic agent.2. A bone void filler material according to claim 1 , wherein the biodegradable matrix comprises collagen claim 1 , chitosan claim 1 , keratin claim 1 , alginate claim 1 , hyaluronic acid or a combination thereof.3. A bone void filler material according to claim 1 , wherein the biodegradable matrix comprises collagen claim 1 , and the collagen comprises human collagen type I claim 1 , human collagen type II claim 1 , human collagen type III claim 1 , human collagen type IV claim 1 , human collagen type V claim 1 , human collagen type VI claim 1 , human collagen type VII claim 1 , or a combination thereof.4. A bone void filler material according to claim 1 , wherein the ceramic particles are slow resorbing and comprise hydroxyapatite (HA) claim 1 , tricalcium phosphate (TCP) or a combination thereof.5. A bone void filler material according to claim 1 , wherein (i) the ceramic cement beads are settable; and (ii) the therapeutic agent is released from the ceramic cement beads in a sustained release over a period of at least 1 day to about 12 months.6. A bone void filler material according to claim 1 , wherein the ceramic cement beads are from about 1 micron to about 200 microns in size.7. A bone void filler ...

Preparation and fully compounded stock for use in medical or dental applications, medical or dental product and use and preparation thereof

According to the invention, a preparation is described which contains at least one calcium compound selected from the group consisting of calcium phosphates, calcium fluorides and calcium fluorophosphates and hydroxyl derivatives and carbonate derivatives of these calcium salts, calcium hydroxides and calcium oxides precipitated using at least one protein component selected from proteins and protein hydrolysates, and at least one crosslinking agent for the protein component and/or non-set cement.

Ceramic Bodies Having Antimicrobial Properties and Methods of Making the Same

A method for making a ceramic body comprised of a ceramic material having an inhibitory effect on bacterial growth is provided. A dental prosthesis may be made of a ceramic material that comprises a molybdenum-containing component on a portion of the prosthesis that contacts the gingival surface of a patient. In one method, a porous zirconia ceramic structure is shaped in the form of a dental prosthesis, and then infiltrated with a molybdenum-containing composition, before sintering to densify the ceramic structure.

CORNEAL INLAY DESIGN AND METHODS OF CORRECTING VISION

A corneal inlay device comprising a flat or flat-like base and a dome or droplet top. The corneal inlay can be used to treat, for example without limitation, presbyopia, while reducing or eliminating the risk of a patient developing corneal haze. 1) A method of treating presbyopia comprising placing in a cornea of a mammalian subject a corneal inlay device of high water content the corneal inlay device comprising a thickness , a diameter , a flat or flat-like base and a dome or droplet shaped top , the dome or droplet shaped top forming a contact angle with the base , wherein the corneal inlay device , when placed in the cornea is effective: to alter a shape of the anterior surface of a cornea , and to increase an eye's ability to increase its power to focus on nearby objects , with a reduced risk of development of corneal haze compared to a control.2) The method of claim 1 , wherein the placing of the corneal inlay device is by cutting a flap in the cornea and positioning the inlay beneath the flap.3) The method of claim 1 , wherein the placing of the corneal inlay device is by positioning the inlay device within a pocket formed in the cornea.4) The method of claim 1 , wherein the placing of the corneal inlay device is in the cornea at a depth of about 100 microns to about 200 microns claim 1 , inclusive.5) The method of claim 1 , wherein the placing of the corneal inlay device is in the cornea at a depth of about 130 microns to about 160 microns claim 1 , inclusive.6) The method of claim 1 , wherein the contact angle is between 1° and 180°.7) The method of claim 1 , wherein the thickness of the corneal inlay ranges from at least 25 microns claim 1 , at least 26 microns claim 1 , at least 27 microns claim 1 , at least 28 microns claim 1 , at least 29 microns claim 1 , at least 30 microns claim 1 , at least 31 microns claim 1 , at least 32 microns claim 1 , at least 33 microns claim 1 , at least 34 microns claim 1 , at least 35 microns claim 1 , at least 36 microns ...

KERATIN BIOCERAMIC COMPOSITIONS

A malleable bone graft composition is described. The composition comprises: (a) keratose; (b) particulate filler; (c) antibiotic; and (d) water. The invention may be provided in sterile form in an container, and optionally lyophilized. Methods of treating a fracture with such compositions are also described. 1. A malleable bone graft composition , comprising:(a) from 1 to 90 percent by weight keratose;(b) from 1 to 90 percent by weight particulate filler;(c) from 0.001 to 5 percent by weight antibiotic; and(d) water to balance;said composition having a viscosity of at least 3 centipoise at a temperature of 37° C.2. The composition of claim 1 , wherein said keratose is alpha keratose claim 1 , gamma keratose claim 1 , or mixtures thereof.3. The composition of claim 1 , wherein said keratose is a mixture of alpha keratose and gamma keratose.4. The composition of claim 1 , wherein said keratose comprises from 10 to 90 percent by weight alpha keratose and from 90 to 10 percent by weight gamma keratose.5. The composition of claim 1 , wherein said keratose is crosslinked keratose.6. The composition of claim 1 , wherein said crosslinked keratose is produced by the process of combining said keratose with transglutaminase in the presence of a calcium initiator.7. The composition of claim 1 , further comprising from 0.001 to 5 percent by weight bone morphogenic protein.8. The composition of claim 1 , wherein said particulate filler is osteoconductive.9. The composition of claim 1 , wherein said particulate filler is selected from the group consisting of tetracalcium phosphate claim 1 , tricalcium phosphate claim 1 , calcium alkali phosphate ceramic claim 1 , bioglass claim 1 , calcium carbonate claim 1 , calcium hydroxide claim 1 , calcium oxide claim 1 , calcium fluoride claim 1 , calcium sulfate claim 1 , magnesium hydroxide claim 1 , hydroxyapatite claim 1 , calcium phosphorus apatite claim 1 , magnesium oxide claim 1 , magnesium carbonate claim 1 , magnesium fluoride ...

NANOFIBERS, NANOTUBES AND NANOFIBER MATS COMRPISING CRYSTALLINE METAL OXIDES AND METHODS OF MAKING THE SAME

Inorganic nanofibers comprise an inorganic matrix material surface functionalized with at least one metal oxide in crystalline form. Crystal growth on external surfaces may occur in substantial alignment with a longitudinal axis of the nanofibers, and the crystals are typically between about 10.0 nm and 30.0 nm in size. The nanofibers may be hollow (i.e., nanotubes) or they may be randomly dispersed together in the form of a nanofiber mat. Methods for making the nanofibers comprise spinning a dispersion comprising linear polymers and metal oxide precursors. 1. An inorganic nanofiber comprising:(a) an inorganic matrix material having an external surface, the inorganic matrix material comprising calcium phosphate; and(b) a plurality of metal oxide crystals, the metal oxide crystals positioned within the inorganic matrix material and/or on the external surface.2. The inorganic nanofiber of claim 1 , wherein at least one of the metal oxide crystals is positioned in substantial alignment with a longitudinal axis of the inorganic nanofiber.3. The inorganic nanofiber of claim 2 , wherein between about 25% and about 50% of the crystals are positioned in substantial alignment with the longitudinal axis.4. The inorganic nanofiber of claim 1 , wherein at least a portion of the metal oxide crystals is oriented at an acute angle relative to the external surface.5. The inorganic nanofiber of claim 1 , wherein at least a portion of the metal oxide crystals is oriented randomly in a variety of directions.6. The inorganic nanofiber of claim 1 , wherein between about 8% and about 20% of the external surface comprises the metal oxide crystals.7. The inorganic nanofiber of claim 1 , wherein the metal oxide crystals comprise a metal oxide selected from the group consisting of VO claim 1 , VO claim 1 , TiO claim 1 , FeO claim 1 , FeO claim 1 , SnO claim 1 , ZrO claim 1 , BaTiO claim 1 , SrTiOand combinations thereof.8. The inorganic nanofiber of claim 1 , wherein the metal oxide crystals ...

Biomedical Materials

A synthetic calcium phosphate-based biomedical material comprising gadolinium. The material may comprises a compound having the general chemical formula: CaGd(PO)(SiO)x(OH)where 0 Подробнее

Resorbable Implant Material Made From Magnesium Or A Magnesium Alloy

The present invention relates to a resorbable implant material made of magnesium or magnesium alloy and to a process for the production thereof. A disadvantage of the known resorbable implants is that their resorption has hitherto only been trackable using x-ray or CT examinations. The invention provides a resorbable implant material comprising homogeneously distributed fluorescent nanodiamonds in a matrix of magnesium or a magnesium alloy. Fluorescent nanodiamonds are biologically nonhazardous and provide a stable emission in the near infrared range due to nitrogen-vacancy centers (NV centres). This allows detection of the implant material in the blood plasma of the patient. The resorbable implant material according to the invention is produced by a process wherein magnesium or a magnesium alloy is melted, nanodiamonds are added to the melt and the melt of magnesium or a magnesium alloy provided with nanodiamonds is subjected to an ultrasound treatment.

BIOACTIVE CRYSTALLIZED GLASS CERAMIC COMPRISING WOLLASTONITE, HYDROXYAPATITE AND DIOPSIDE, AND USE THEREOF

The present invention relates to a glass ceramic composition comprising SiO, Ca(OH), CaF, BO, MgO, and hydroxyapatite; a bioactive crystallized glass ceramic comprising each of CaSiO, Ca(PO)(OH), and CaMgSiOin an amount of 20% to 60% by weight; an implant for early osseointegration comprising the glass ceramic; and a method for manufacturing the implant. 1. A glass ceramic composition comprising SiO , Ca(OH) , CaF , BO , MgO , and hydroxyapatite.2. The glass ceramic composition of claim 1 , wherein the composition comprises SiOin an amount of 15% to 45% by weight claim 1 , Ca(OH)in an amount of 20% to 45% by weight claim 1 , CaFin an amount of 0.01% to 5% by weight claim 1 , BOin an amount of 0.01% to 5% by weight of claim 1 , MgO in an amount of 0.01% to 20% by weight claim 1 , and hydroxyapatite in an amount of 15% to 45% by weight based on the total weight of the glass ceramic composition.3. The glass ceramic composition of claim 1 , wherein the composition comprises SiOin an amount of 15% to 45% by weight claim 1 , Ca(OH)in an amount of 25% to 45% by weight claim 1 , CaFin an amount of 0.01% to 3.5% by weight claim 1 , BOin an amount of 0.01% to 3.5% by weight of claim 1 , MgO in an amount of 0.01% to 20% by weight claim 1 , and hydroxyapatite in an amount of 15% to 45% by weight based on the total weight of the glass ceramic composition.4. The glass ceramic composition of claim 1 , wherein the composition further comprises Na.5. The glass ceramic composition of claim 4 , wherein the Na is contained in an amount of 0.1% to 2% by weight based on the total weight of the glass ceramic composition.6. A crystallized glass ceramic comprising CaSiO claim 4 , Ca(PO)(OH) claim 4 , and CaMgSiO.7. The crystallized glass ceramic of claim 4 , wherein the crystallized glass ceramic is formed by sintering the glass ceramic composition of at a temperature of 900° C. to about 1 claim 4 ,100° C.8. The crystallized glass ceramic of claim 6 , wherein CaSiOis wollastonite claim 6 , ...

BIOMEDICAL MATERIALS

A synthetic calcium phosphate-based biomedical material comprising gadolinium. The material may comprises a compound having the general chemical formula: CaGd(PO)(SiO)x(OH)where 0 Подробнее

Implantable Medical Instrument Preform, Implantable Medical Instrument and Preparation Method Thereof

Disclosed are an implantable medical device, a preparation method thereof and an implantable medical device preform for the preparation of the implantable medical device. The implantable medical device comprises a metal basal body ( 21 ) and a polymer film layer ( 22 ) covering the surface of the metal basal body ( 21 ) and preventing endothelium growth and covering, and also comprises a transitional body ( 23 ), which is located between the metal basal body ( 21 ) and the polymer film layer ( 22 ) and covers at least part of the surface of the metal basal body ( 21 ), wherein the transitional body ( 23 ) is connected to the polymer film layer ( 22 ) and the metal basal body ( 21 ). By arranging the transitional body ( 23 ) to be connected to the polymer film layer ( 22 ) and the metal basal body ( 21 ), the polymer film layer ( 22 ) will not easily fall off when being implanted into a human body.

Methods, systems, and compositions for promoting bone growth

The present invention relates to novel bone compositions for locally delivering a therapeutic agent to the site of a bone defect. Therapeutic agents may promote repair of the bone defect and/or treat conditions or disorders such as pain, inflammation, cancer, and infection. The compositions include calcium phosphate cements and a demineralized bone matrix or a collagen sponge. The compositions are useful for implantation in a patient at the site of a bone defect.

TRIZONAL MEMBRANES FOR PERIOSTEUM REGENERATION

Disclosed are trilaminate collagen-based tissue scaffolds that exhibit remarkable morphological mimicry to that of the natural mammalian periosteum tissue they are useful in remodeling. In particular embodiments, periosteum-modeling trizonal membranes for reforming and regrowing human bone tissue are provided that are composed of a first zone of compact collagen, a second layer of collagen-elastin, and a third layer of biomineralized collagen. 1. A biocompatible , multilayer , tissue scaffold , comprising:(a) a first, upper layer that comprises compact collagen;(b) a second, middle layer that comprises collagen and elastin; and(c) a third, lower layer that comprises a mineralized collagen.2. The biocompatible claim 1 , multilayer claim 1 , tissue scaffold of claim 1 , wherein the first claim 1 , upper layer is non-porous.3. The biocompatible claim 1 , multilayer claim 1 , tissue scaffold of claim 1 , wherein the first claim 1 , upper layer comprises Type I collagen.4. The biocompatible claim 3 , multilayer claim 3 , tissue scaffold of claim 3 , wherein the Type I collagen is obtained from mammalian tendon.5. The biocompatible claim 1 , multilayer claim 1 , tissue scaffold of claim 1 , wherein the second claim 1 , middle layer comprises human or bovine elastin.6. The biocompatible claim 1 , multilayer claim 1 , tissue scaffold of claim 1 , wherein the second claim 1 , middle layer promotes vascularization claim 1 , and recapitulates one or more of the elastic features of human periosteal tissue.7. The biocompatible claim 1 , multilayer claim 1 , tissue scaffold of claim 1 , in which the third claim 1 , lower layer comprises hydroxyapatite.8. The biocompatible claim 7 , multilayer claim 7 , tissue scaffold of claim 7 , wherein the third claim 7 , lower layer comprises magnesium-doped hydroxyapatite.9. The biocompatible claim 1 , multilayer claim 1 , tissue scaffold of claim 1 , wherein the collagen is human or bovine Type I collagen claim 1 , and the elastin is ...

TISSUE REPAIR AND REPLACEMENT

Tissue fixation devices are provided. The devices include a first component and a second component, the components having different rates of in vivo degradation. The first component and second component are arranged so that, upon degradation of one of the components, the other component provides a scaffold into which bone can grow. 148-. (canceled)49. A method of tissue repair or replacement , comprising:implanting in a patient a tissue repair or replacement device having at least a first and a second components, the at least first and second components having different relative rates of in vivo degradation, the first component having a higher rate of in vivo degradation than the second component, and the first and second components being arranged relative to each other so that, after implantation of the device, the first component degrades in vivo leaving a scaffold formed of the second component, the scaffold having pores into which tissue can infiltrate.50. The method of claim 49 , wherein the scaffold formed from degradation of the first or second component of the tissue repair or replacement device has a pore size of about 20-2000 microns.51. The method of claim 49 , wherein the scaffold formed from degradation of the first or second component has a porosity of about 10-90%.52. The method of claim 49 , wherein one of the first and second components of the tissue repair or replacement device comprises a ceramic.53. The method of claim 52 , wherein the other component of the implanted tissue repair or replacement device comprises a polymer.54. The method of claim 49 , wherein the first component of the tissue repair or replacement device comprises ceramic and the second component comprises polymer.55. The method of claim 49 , wherein there is at least an 8 week difference between the rate of in vivo degradation of the first and second components of the implanted tissue repair or replacement device.56. The method of claim 52 , wherein there is at least an 8 week ...

OSTEOCONDUCTIVE COATING OF IMPLANTS MADE OF PLASTIC

The invention relates to biomaterials based on plastics, such as polyaryl polyether ketone (PEK), and to methods for producing and using same. The following describes how a mechanically stable coating made of a porous bone substitute material, e.g. Nano Bone®, is applied to polyaryl polyether ketone (PEK), e.g. polyether ether ketone (PEEK), as a result of which the problem of poor cell adhesion on plastics surfaces of this kind can be solved. The bone substitute material can be applied both dry as a powder and also in a wet spraying method. The coating is a result of briefly melting the polymer surface and the resulting partial penetration of the previously applied layer. In the process, the molten polymer penetrates into nanopores of the bone substitute material and thus establishes a firm connection. 1. A plastic implant characterized in that a highly porous bone substitute material is embedded in the surface layer into the plastic in the areas in which the bone is to grow onto the implant , wherein the bone substitute material protrudes from the surface.2. The plastic implant according to characterized in that the porosity of the bone replacement material is in the range of 20 to 80% claim 1 , the average pore size is in the range of 10 to 100 nm claim 1 , the surface layer of the plastic has a thickness of 1 μm to 100 μm and/or the bone substitute material protrudes from the plastic preferably in the range of from 0.1 to 30 μm.3. The plastic implant according to characterized in that the bone substitute material is crystal-line hydroxyapatite (HA) embedded in an amorphous porous matrix of silicon dioxide claim 1 , wherein the HA has a share of 20 to 90 percent by weight in terms of HA and silicon dioxide claim 1 , is present as granulate having a size preferably in the range of 1 to 50 μm or is a continuous layer having a preferred layer thickness of 1 to 20 μm.4. The plastic implant according to claim 1 , characterized in that the bone substitute material is ...

ZIRCONIUM OXIDE-BASED COMPOSITE MATERIAL

The invention relates to a method for producing a ceramic composite material, and a ceramic composite material which in particular is damage-tolerant. 116.-. (canceled)17. A composite material comprising:a ceramic matrix, said ceramic matrix comprising zirconium oxide and at least one secondary phase dispersed therein, wherein the matrix composed of zirconium oxide has a proportion of at least 51 vol.-% of composite material, and that the secondary phase has a proportion of 1 to 49 vol.-% of composite material, wherein 90 to 99% of the zirconium oxide is present in the tetragonal phase based on the total zirconium oxide portion; andwherein the tetragonal phase of the zirconium oxide is stabilized by at least one member selected from the group consisting of chemical stabilization and mechanical stabilization.18. A composite material according to claim 17 , wherein the matrix composed of zirconium oxide has an average grain size of 0.1 to 2.0 μm.19. A composite material according to claim 17 , the chemical stabilization is via addition of a chemical stabilizer selected from the group consisting of YO claim 17 , CeO claim 17 , GdO claim 17 , SmO claim 17 , and ErO; wherein a total content of chemical stabilizer is <12 mol-% based on a zirconium oxide content.20. A composite material according to claim 19 , wherein a content of YOis ≦3 mol claim 19 , based on the zirconium oxide content.21. A composite material according to claim 17 , wherein at least one of the zirconium oxide or the secondary phase contain a soluble substituent.22. A composite material according to claim 21 , wherein the soluble substituent is selected from the group consisting of Cr claim 21 , Fe claim 21 , Mg claim 21 , Ca claim 21 , Ti claim 21 , Y claim 21 , Ce claim 21 , a lanthanide and V.23. A composite material according to claim 22 , wherein the soluble substituent is an oxide.24. A composite material according to claim 17 , wherein the secondary phase includes a dispersoid which claim 17 , ...

COMPOSITE MATERIAL AND BIOIMPLANT

A composite material in one of embodiments includes a crystal phase of titanium fluoride and a metal crystal phase of titanium. The crystal phase of the titanium fluoride is present in a first region located away from a surface in a depth direction. 1. A composite material , comprising:a crystal phase of titanium fluoride, the crystal phase being present in a first region located away from a surface in a depth direction; anda metal crystal phase of titanium.2. The composite material according to claim 1 , wherein the titanium fluoride is TiOF.3. The composite material according to claim 1 , wherein the metal crystal phase comprises a first phase comprising fluorine.4. The composite material according to claim 3 , wherein the first phase is located in the first region.5. The composite material according to claim 3 , whereinthe metal crystal phase further comprises a second phase located more inside than the first phase, andthe second phase comprises no fluorine.6. The composite material according to claim 5 , wherein the second phase is located more inside than the first region.7. The composite material according to claim 1 , further comprising:an amorphous phase comprising titanium and fluorine.8. The composite material according to claim 7 , further comprising:a mixed phase comprising the amorphous phase, the crystal phase of the titanium fluoride, and the metal crystal phase.9. The composite material according to claim 1 , wherein a fluorine concentration reaches a maximum value at a portion located more inside than the surface.10. The composite material according to claim 9 , wherein the fluorine concentration increases to the maximum value when going from the surface toward inside.11. The composite material according to claim 9 , wherein the fluorine concentration reaches the maximum value in the first region.12. The composite material according to claim 11 , wherein the fluorine concentration reaches the maximum value at a side closer to the surface than a ...

BONE GRAFT SUBSTITUTE

A bone graft substitute in the form of an implantable three-dimensional scaffold that includes calcium phosphate and has pores. The scaffold is impregnated with a calcium and/or phosphate containing substance, and the dissolution rate DRof the scaffold is slower than the dissolution rate DRof the calcium and/or phosphate containing substance.

Reinforced Bone Scaffold

Scaffolds for use in bone tissue engineering include a skeleton and a host component. Methods of preparation of scaffolds include identification of biodegradation properties for the skeleton and the host component. The skeleton is constructed to form a three-dimensional shape. The skeleton is constructed of a first material and has a first rate of biodegradation. The host component fills the three-dimensional shape formed by the skeleton. The host component is constructed of a second material and has a second rate of biodegradation. The first rate of biodegradation is slower than the second rate of biodegradation.

Method for producing calcium phosphate molded article, calcium phosphate molded article, and material for transplantation

Provided are a method for rapidly producing a calcium phosphate molded article having high strength with high shaping precision, a calcium phosphate molded article produced by the method, and a material for transplantation. Disclosed is a method for producing a calcium phosphate molded article, the method including: step (a) of forming a layer containing a calcium phosphate powder having a ratio of the numbers of atoms of Ca/P of 1.4 to 1.8 on a substrate; and step (b) of producing a calcium phosphate molded article by jetting an organic acid solution having a pH of 3.5 or lower and including an organic acid whose calcium salt has a solubility in water of 1 g/100 mL or less, through a nozzle unit into a liquid droplet state, thereby dropping the organic acid solution onto the layer containing a calcium phosphate powder formed in step (a).

Selenium-doped hydroxyapatite and preparation method thereof

The invention relates to a selenium-doped hydroxyapatite and a preparation method thereof. The selenium-doped hydroxyapatite provided is a single crystal comprising a rod-like structure, a uniform morphology, and a good dispersibility. The preparation method comprises adding a mixed solution of a phosphate and a selenite dropwise to a mixed solution of a calcium salt and a dispersing agent, and reacting for 1.5-2.5 hrs at a controlled temperature of 80-90° C., to obtain a solution of a calcium phosphate amorphous precursor, followed by performing a hydrothermal reaction at 190-210° C., to obtain a selenium-doped hydroxyapatite comprising a rod-like structure. Compared with selenium-doped hydroxyapatite with severe agglomeration, the selenium-doped hydroxyapatite provided in the present invention comprises good dispersibility and able to have better prevention of clogging problem in human body when in use, thus having a good prospect using as a multi-functional new material for bone repair in patients as a repair material for bone defects, an anti-tumor, etc.

LIPID COMPOSITIONS CONTAINING BIOACTIVE FATTY ACIDS

Provided herein is technology relating to lipid compositions containing bioactive fatty acids and particularly, but not exclusively, to compositions and methods related to the production and use of structured lipid compositions containing sciadonic and/or pinoleic acid alone or in combination with other bioactive fatty acids including, but not limited to, eicosapentaenoic acid, docosahexaenoic acid, conjugated linoleic acid, and non-β-oxidizable fatty acid analogues such as tetradecylthioacetic acid. 2. The formulation of claim 1 , wherein said non-methylene-interrupted fatty acid moiety is selected from the group consisting of a 5 claim 1 ,11 claim 1 ,14-eicosatrienoic acid moiety claim 1 , a 5 claim 1 ,9 claim 1 ,12-cis-octadecatrienoic acid moiety; and a 5 claim 1 ,11 claim 1 ,14 claim 1 ,17-eicosatetraenoic acid moiety and combinations thereof.3. The formulation of claim 1 , wherein said second bioactive lipid moiety is selected from the group consisting of an omega-3 fatty acid moiety claim 1 , a non-beta-oxidizable fatty acid moiety claim 1 , a conjugated linoleic acid moiety and combinations thereof.4. The formulation of claim 3 , wherein said omega-3 fatty acid moiety is selected from the group consisting of an all-cis-5 claim 3 ,8 claim 3 ,11 claim 3 ,14 claim 3 ,17-eicosapentaenoic acid moiety claim 3 , an all-cis-7 claim 3 ,10 claim 3 ,13 claim 3 ,16 claim 3 ,19-docosapentaenoic acid moiety claim 3 , and an all-cis-4 claim 3 ,7 claim 3 ,10 claim 3 ,13 claim 3 ,16 claim 3 ,19-docosahexaenoic acid moiety and combinations thereof.5. The formulation of claim 3 , wherein said non-beta-oxidizable fatty acid moiety is selected from the group consisting of a tetradecylthioacetic acid (TTA) moiety and a tetradecylselenoacetic acid (TSA) moiety and combinations thereof.6. The formulation of claim 3 , wherein said conjugated linoleic acid moiety is selected from the group consisting of a c9 claim 3 ,t11 conjugated linoleic acid moiety claim 3 , a t10 claim 3 ,c12 ...

METHODS OF USING WATER-SOLUBLE INORGANIC COMPOUNDS FOR IMPLANTS

A method for controlling generation of biologically desirable voids in a composition placed in proximity to bone or other tissue in a patient by selecting at least one water-soluble inorganic material having a desired particle size and solubility, and mixing the water-soluble inorganic material with at least one poorly-water-soluble or biodegradable matrix material. The matrix material, after it is mixed with the water-soluble inorganic material, is placed into the patient in proximity to tissue so that the water-soluble inorganic material dissolves at a predetermined rate to generate biologically desirable voids in the matrix material into which bone or other tissue can then grow. 1199-. (canceled)200. A bone cement comprising a poorly water-soluble bioactive implantable thermoplastic matrix material and , mixed with the matrix material , at least one type of bioactive glass particles having a selected particle size , a selected particle shape and a selected(particle dissolution rate , wherein once placed in proximity to tissue as an implant or with a separate implant , bodily fluids gradually dissolve the bioactive glass particles to provide an effective amount of at least one non-antibiotic antimicrobial agent.201. The bone cement according to where the dissolution of the bioactive glass particles creates a porous implant surface or a textured implant surface.202. The bone cement according to wherein the thermoplastic matrix material includes polymethylmethacrylate.203100. The bone cement according to wherein the bioactive glass particles have an average particle size below microns.204. The bone cement according to wherein the bioactive glass particles generate at least two elution profiles by possessing (i) at least two different particle sizes claim 200 , (ii) at least two different glass formulations having different dissolution rates claim 200 , and/or (iii) at least two different antimicrobial constituents.205. The bone cement according to wherein the ...

Implants having a drug load of an oxysterol and methods of use

Provided is a compression resistant implant configured to fit at or near a bone defect to promote bone growth. The compression resistant implant comprises a biodegradable polymer in an amount of about 0.1 wt % to about 20 wt % of the implant and a freeze-dried oxysterol in an amount of about 5 wt % to about 90 wt % of the implant. Methods of making and use are further provided.

Bone graft implants containing allograft

Synthetic, bioactive ultra-porous bone graft materials having an engineered porosity, and implants formed from such materials are provided. In particular, these implants comprise bioactive glass and incorporate allograft material for osteoinduction. The implants are suitable for bone tissue regeneration and/or repair.

Bone matrix compositions and methods

An osteoinductive composition, corresponding osteoimplants, and methods for making the osteoinductive composition are disclosed. The osteoinductive composition comprises osteoinductive factors, such as may be extracted from demineralized bone, and a carrier. The osteoinductive composition is prepared by providing demineralized bone, extracting osteoinductive factors from the demineralized bone, and adding the extracted osteoinductive factors to a carrier. Further additives such as bioactive agents may be added to the osteoinductive composition. The carrier and osteoinductive factors may form an osteogenic osteoimplant. The osteoimplant, when implanted in a mammalian body, can induce at the locus of the implant the full developmental cascade of endochondral bone formation including vascularization, mineralization, and bone marrow differentiation. Also, in some embodiments, the osteoinductive composition can be used as a delivery device to administer bioactive agents.

BONE REGENERATION MATERIAL

A method of manufacturing a bone substitute structure for reconstruction of bone material in a patient. The method comprises the steps of providing data reflecting a cavity in a bone of a patient, defining and modelling a three dimensional structure corresponding to the cavity in the bone; and providing an individualized bone substitute structure, corresponding to the defined and modeled three dimensional structure, by combining calcium phosphate cement, growth factors and the patient's own un-coagulated blood. 1. A method of manufacturing a bone substitute structure in reconstruction of bone material in a patient , the method comprising:I. providing data reflecting a cavity in a bone of a patient;II. defining and modelling a three dimensional structure corresponding to the cavity in the bone; andIII. providing an individualized bone substitute structure, corresponding to the defined and modeled three dimensional structure in II, by combining calcium phosphate cement, growth factors and the patient's own un-coagulated blood, wherein the individualized bone substitute structure in III is obtained by using a rapid prototype machine to generate the individualized bone substitute structure by additive layer manufacturing, wherein a layer upon layer sequence of the calcium phosphate cement, the individualized growth factors and the individualized un-coagulated blood prints the individualized bone substitute structure, and wherein the rapid prototype machine comprises at least a first printing tube for the calcium phosphate cement, a second printing tube for the individualized un-coagulated blood and a third printing tube for the growth factors, wherein these at least three printing tubes are computer controlled regarding flow-rate and the layer upon layer sequence.2. The method according to claim 1 , wherein the data in I is obtained by:scanning the hard and soft tissue of the bone cavity, andgenerating a digital data impression of the bone cavity.3. The method according ...

COMPOSITE MATERIAL AND USES THEREOF

A composite material for a medical implant includes a matrix of magnesium or magnesium alloy, and a catalyst which is dispersed within the matrix. The catalyst has the capacity to reduce an amount of hydrogen gas released from the matrix when the matrix is being degraded inside the patient. 2. A composite material according to claim 1 , wherein the matrix is adapted to being degraded in an aqueous environment at a pH below 11.5.3. A composite material according to claim 1 , wherein the catalyst is selected from the group consisting of platinum (Pt) claim 1 , ruthenium (Ru) claim 1 , rhodium (Rh) claim 1 , palladium (Pd) claim 1 , osmium (Os) claim 1 , iridium (Ir) claim 1 , niobium (Nb) claim 1 , molybdenum (Mo) claim 1 , tantalum (Ta) claim 1 , tungsten (W) claim 1 , metal oxide claim 1 , vanadium (V) based oxide claim 1 , nickel (Ni) based oxide claim 1 , or mixtures thereof.4. A composite material according to claim 1 , wherein 0.001-1% by weight of the composite material consists of the catalyst.5. A composite material according to claim 1 , wherein the catalyst is dispersed throughout the entire matrix of magnesium or magnesium alloy.6. A composite material according to claim 1 , wherein the catalyst is dispersed throughout the matrix such that there is always active catalyst present on a surface of the matrix.7. A medical implant comprising a composite material according to .8. The medical implant according to claim 7 , wherein the medical implant is selected from the group consisting of a coronary stent claim 7 , a suture claim 7 , a vascular closure device claim 7 , a device for temporary attachment of a pacemaker or a neurostimulator claim 7 , an orthopedic implant claim 7 , an extravascular closure device claim 7 , and a clip.9. A method for preparing a composite material according to claim 1 , comprising dispersing a catalyst into the matrix by sintering a mixture of the matrix and the catalyst.10. A method for producing a medical implant according to ...

Biodegradable Composite Scaffold for Repairing Defects in Load-Bearing Bones

A tissue scaffold for repair and regeneration of bone hard tissue or muscle, skin, or organ soft tissue, including load-bearing bone tissue, the scaffold comprising a core of biocompatible, biodegradable inorganic glass fibers; and a biocompatible, biodegradable, flexible polymer film surrounding the core and adhered to the core. 1. A tissue scaffold for repair and regeneration of bone hard tissue or muscle , skin , or organ soft tissue , including load-bearing bone tissue , the scaffold comprising:a core of biocompatible, biodegradable inorganic glass fibers; anda biocompatible, biodegradable, flexible polymer film surrounding the core and adhered to the core;wherein the flexural strength of the composite scaffold is at least about 40 MPa.2. The scaffold of wherein the polymer film has a thickness between about 5 microns and about 1000 microns.3. The scaffold of wherein the polymer film encapsulates the scaffold body along some fraction of its length but not at its ends claim 1 , so the scaffold body is open with its core exposed at its ends.4. The scaffold of the wherein the flexural strength of the core is less than about 40 MPa.5. The scaffold of the wherein the flexural strength of the core is less than about 10 MPa.6. The scaffold of the wherein the core has a flexural strength which is less than about 50% of the flexural strength of the scaffold comprising the core and the polymer film.7. The scaffold of wherein the core has a flexural strength which is less than about 10% of the flexural strength of the scaffold comprising the core and the polymer film.8. The scaffold of wherein the fibers of the core are bonded together.9. The scaffold of wherein the fibers of the core are thermally fused together.10. The scaffold of wherein at least about 75 vol % of the fibers are longitudinally co-aligned and lie generally lengthwise along the scaffold central axis claim 1 , are generally free of helical orientation about the scaffold central axis claim 1 , and are ...

BONE SUBSTITUTE MATERIAL

A biphasic calcium phosphate/hydroxyapatite (CAP/HAP) bone substitute material having a sintered CAP core and a closed epitactically grown layer of nanocrystalline HAP deposited on the external surface of the sintered CAP core, wherein the closed epitactically grown layer of nanocrystalline HAP deposited on the external surface of the sintered CAP core has a homogeneous coarse external surface comprising flat crystal platelets, which shows an enhanced osteogenic response, a method of promoting bone formation, bone regeneration and/or bone repair by implanting the biphasic calcium phosphate/hydroxyapatite (CAP/HAP) bone substitute material, and a process of preparation thereof. 1. A biphasic calcium phosphate/hydroxyapatite (CAP/HAP) bone substitute material comprising a sintered CAP core and a closed epitactically grown layer of nanocrystalline HAP deposited on the external surface of the sintered CAP core , whereby the epitactically grown nanocrystals have the same size and morphology as human bone mineral , wherein the closed epitactically grown layer of nanocrystalline HAP deposited on the external surface of the sintered CAP core has a homogeneous coarse external surface comprising flat crystal platelets.2. The biphasic calcium phosphate/hydroxyapatite (CAP/HAP) bone substitute material according to claim 1 , wherein the coarse surface comprises epitactically grown nanocrystalline hydroxyapatite platelets forming an interlocked network of platelets with sizes of 0.2 to 20 μm as determined by Scanning Electron Microscopy (SEM).3. The biphasic calcium phosphate/hydroxyapatite (CAP/HAP) bone substitute material according to claim 1 , wherein the coarse surface comprises epitactically grown nanocrystalline hydroxyapatite platelets forming an interlocked network of platelets with sizes of 0.5 to 5 μm as determined by Scanning Electron Microscopy (SEM).4. The biphasic calcium phosphate/hydroxyapatite (CAP/HAP) bone substitute material according to claim 1 , wherein ...

REINFORCED BIOLOGIC MATERIAL

The present disclosure provides an implantable medical device comprising a composite graft material including a first biologic component, such as an acellular tissue matrix, and a second non-biologic component. 1. An implantable medical device , comprising:a group of first elongate non-biologic elements;a sheath wrapped around and surrounding at least a portion of the group of first elongate non-biologic elements; andat least one second elongate non-biologic element, wherein the at least one second element secures at least one end portion of the group of first elongate non-biologic elements.2. The implantable medical device of claim 1 , wherein at least a portion of the group of first elongate non-biologic elements are under a tensile or compressive stress prior to implantation.3. The implantable medical device of claim 2 , wherein at least a portion of the group of first elongate non-biologic elements are loaded with the tensile or compressive stress independently of the sheath.4. The implantable medical device of claim 1 , wherein at least a portion of the group of first elongate non-biologic elements and the sheath are loaded together with a tensile or compressive stress.5. The implantable medical device of claim 2 , wherein the group of first elongate non-biologic elements have a higher load capacity than the sheath at the time of implantation.6. The implantable medical device of claim 5 , wherein the sheath has a higher load capacity than the group of first elongate non-biologic elements after implantation and following growth of native cells within the sheath.7. The implantable medical device of claim 1 , wherein the sheath comprises a non-biologic material.8. The implantable medical device of claim 1 , wherein the sheath comprises a biologic component including a biomatrix.9. The implantable medical device of claim 8 , wherein the biomatrix comprises an acellular tissue matrix or a particulate acellular tissue matrix.10. The implantable medical device of ...

NEW SINGLE-STEP MANUFACTURING PROCESS FOR FOAMED BIOMATERIALS

Processes for the preparation of biomaterials, in particular foams and solid structures, suitable for bone surgery and odontology, bone regeneration, bone defect fillings, stabilizing bone fractures, coating of prostheses or implants, fixing of prostheses or implants, drug delivery systems, and tissue engineering scaffolds, and to the biomaterials obtained thereby. Besides that, this invention, also relates to self-setting calcium phosphate foams which may be obtained by simultaneously mixing and foaming of a powder phase and a liquid phase. 1. A process for the preparation of a self-setting calcium phosphate foam , comprising a single step of simultaneous mixing and foaming a powder phase and a liquid phase , wherein the powder phase comprises at least one calcium source and at least one phosphate source , wherein the liquid phase is an aqueous solution , wherein the powder phase , the liquid phase or both contain at least one additive selected from the group consisting of surfactants and foaming agents , and wherein the mixing and simultaneous foaming are performed by back-and-forth movements of the material through a narrow connection between two containers , one of them containing the powder phase and the other one the liquid phase.2. The process according to claim 1 , wherein the simultaneous mixing and foaming are performed by mechanical whipping at a rotation speed between 1000 rpm and 15000 rpm.3. (canceled)4. (canceled)5. The process according to claim 1 , wherein the two containers are two syringes and the back-and-forth movements are performed through a tip-to-tip connection between the two syringes.6. The process according to claim 1 , wherein at least one of the additives is a non-ionic surfactant.7. The process according to claim 6 , wherein the non-ionic surfactant is polyoxyethylene sorbitan monooleate.8. The process according to claim 7 , wherein the polyoxyethylene sorbitan monooleate is added in the liquid phase at a weight % with respect to the ...

DYNAMIC BIOACTIVE NANOFIBER SCAFFOLDING

A resorbable bone graft scaffold material, including a plurality of overlapping and interlocking fibers defining a scaffold structure, plurality of pores distributed throughout the scaffold, and a plurality of glass microspheres distributed throughout the pores. The fibers are characterized by fiber diameters ranging from about 5 nanometers to about 100 micrometers, and the fibers are a bioactive, resorbable material. The fibers generally contribute about 20 to about 40 weight percent of the scaffold material, with the microspheres contributing the balance. 121-. (canceled)22. A resorbable tissue graft scaffold material , consisting essentially of:a plurality of overlapping and interlinking polymer-free, bioactive ceramic fibers defining a three-dimensional, flexible, porous scaffold; anda plurality of bioactive, resorbable glass or ceramic beads distributed throughout the porous scaffold;wherein the beads contribute from 60 weight percent to 95 weight percent of the tissue graft scaffold material and wherein the tissue graft scaffold is polymer-free.23. The tissue graft scaffold material of claim 22 , wherein the fibers are composed of a material selected from the group consisting of calcium phosphate claim 22 , hydroxyapatite claim 22 , bioactive glass and combinations thereof.24. The tissue graft scaffold material of claim 22 , wherein the beads are composed of the same material as the fibers.25. The tissue graft scaffold material of claim 22 , wherein the beads are solid.26. The tissue graft scaffold material of claim 22 , wherein the beads are generally spherical.27. The tissue graft scaffold material of claim 22 , wherein the beads are hollow to define respective inner core volumes claim 22 , the inner core volumes being filled with medicines claim 22 , nutritive supplements claim 22 , antibiotics claim 22 , antivirals claim 22 , vitamins or combinations thereof.28. The tissue graft scaffold material of claim 22 , wherein the beads are porous.29. The tissue ...

MANUFACTURING METHOD FOR GRANULE

The purpose of the present invention is to provide a method for producing granules of having a uniform size. To this end, the present invention provides a method for producing granules, the method characterized by including preparing an organic member solution, uniformly dispersing an inorganic member in the organic member solution at a weight ratio of 1 to 10 based on an organic member to form an organic-inorganic composite solution, spraying the organic-inorganic composite solution in an electrostatic charge manner, and polymerizing the sprayed organic-inorganic composite solution to form a hydrogel phase. The production method of the present invention has advantages in that granules having a uniform size may be mass-produced in a short time and the granules may be produced at a high yield. Accordingly, the production method of the present invention has advantages in that the method may be applied to a variety of fields, such as a pharmaceutical field, a medical field, a cosmetics field, and a food field and that the method may replace a conventional spray drying method. 1. A method for manufacturing granules , the method comprising:preparing an organic member solution;uniformly dispersing an inorganic member in the organic member solution at a weight ratio of 1 to 10 based on an organic member to form an organic-inorganic composite solution;spraying the organic-inorganic composite solution in an electrostatic charge manner; andpolymerizing the sprayed organic-inorganic composite solution to form a hydrogel phase.2. The method of claim 1 ,wherein the weight ratio of the inorganic member dispersed in the organic member solution to the organic member is 5 to 10.3. The method of claim 1 , further comprising claim 1 ,after forming the organic-inorganic composite solution, dispersing the inorganic member with a rotation and revolution mixer and stirring the resultant composite solution with an ultrasonic mixer.4. The method of claim 1 ,wherein the polymerizing of the ...

METAL MATRIX COMPOSITE ORTHOPEDIC REPLACEMENTS

Orthopedic replacements include are formed at least partially of composite materials including a metal matrix with reinforcing carbon fiber integrated into the matrix. The composite materials have substantially lower density than metal, and are expected to have appreciable strength. The orthopedic replacements can include a bone attachment portion and a load bearing portion. In some versions, the orthopedic replacements can include a core formed of the composite material, with a shape completion portion, formed for example from plastic, at least partially coating the core. 1. An orthopedic replacement comprising:a bone connection portion, configured to contact and adhere to bone; and a continuous metal matrix; and', 'a reinforcing carbon fiber that is at least partially encapsulated within the continuous metal matrix., 'a load bearing portion, configured to bear a load and formed, at least in part, of a carbon fiber metal matrix material (CF-MMC) comprising2. The orthopedic replacement as recited in claim 1 , wherein the at least one reinforcing carbon fiber is fully encapsulated within the metal matrix.3. The orthopedic replacement as recited in claim 1 , wherein the at least one reinforcing carbon fiber is partially encapsulated within the metal matrix.4. The orthopedic replacement as recited in claim 1 , wherein the at least one reinforcing carbon fiber comprises a plurality of spatially separated layers of reinforcing carbon fiber.5. The orthopedic replacement as recited in claim 1 , having density less than 7 g/cm.6. The orthopedic replacement as recited in claim 1 , having density less than 6 g/cm.7. The orthopedic replacement as recited in claim 1 , having density less than 5 g/cm.8. The orthopedic replacement as recited in claim 1 , wherein the continuous metal matrix comprises an alloy of iron claim 1 , carbon claim 1 , and at least one element selected from a group including: Mn claim 1 , Ni claim 1 , Cr claim 1 , Mo claim 1 , B claim 1 , Ti claim 1 , V ...

Compositions and Methods for Spine Fusion Procedures

The present invention provides compositions and methods for promoting fusion of bones in spine fusion procedures. In some embodiments, a method of performing a spine fusion procedure comprises providing a composition comprising PDGF disposed in a biocompatible matrix and applying the composition to a site of desired spine fusion.

BONE SUBSTITUTE MATERIAL

A biphasic calcium phosphate/hydroxyapatite (CAP/HAP) bone substitute material having a sintered CAP core and at least one closed epitactically grown layer of nanocrystalline HAP deposited on the external surface of the sintered CAP core, whereby the epitactically grown nanocrystals have the same size and morphology as human bone mineral, wherein the closed epitactically grown layer of nanocrystalline HAP deposited on the external surface of the sintered CAP core has a non-homogeneous external surface comprising individual clusters of flat crystal platelets consisting of epitactically grown HAP nanocrystals and coarse areas between the individual clusters, whereby the percentage of the coarse areas between the individual clusters as measured by SEM is at least 20% of the total surface, which material shows an increased capacity to induce bone formation, and a process of preparation thereof. 1. A biphasic calcium phosphate/hydroxyapatite (CAP/HAP) bone substitute material comprising a sintered CAP core and at least one closed epitactically grown layer of nanocrystalline HAP deposited on the external surface of the sintered CAP core , whereby the epitactically grown nanocrystals have the same size and morphology as human bone mineral , wherein the closed epitactically grown layer of nanocrystalline HAP deposited on the external surface of the sintered CAP core has a non-homogeneous external surface comprising individual clusters of flat crystal platelets consisting of epitactically grown HAP nanocrystals and coarse areas between the individual clusters , whereby the percentage of the coarse areas between the individual clusters as measured by SEM is at least 20% of the total surface.2. The biphasic calcium phosphate/hydroxyapatite (CAP/HAP) bone substitute material according to claim 1 , wherein the coarse areas between the individual clusters consist of platelets of HAP nanocrystals with individual platelet sizes of 0.2 to 5 μm as determined by SEM.3. The biphasic ...

BONE REPLACEMENT MATERIALS

Particular aspects provide novel devices for bone tissue engineering, comprising a metal or metal-based composite member/material comprising an interior macroporous structure in which porosity may vary from 0-90% (v), the member comprising a surface region having a surface pore size, porosity, and composition designed to encourage cell growth and adhesion thereon, to provide a device suitable for bone tissue engineering in a recipient subject. In certain aspects, the device further comprises a gradient of pore size, porosity, and material composition extending from the surface region throughout the interior of the device, wherein the gradient transition is continuous, discontinuous or seamless and the growth of cells extending from the surface region inward is promoted. 1. A method of producing a porous metal or metal-based composite device , comprising:obtaining input data from bone imaging scans of a patient;selecting at least one of a density, a modulus of elasticity or a compression strength of a device for bone tissue engineering based on the obtained input data from the bone imaging scans of the patient; andforming the device for bone tissue engineering to have the selected at least one of the density, the modulus of elasticity or the compression strength, wherein the device for bone tissue engineering includes a member of a biocompatible metal or metal-based composite, the member having an exterior surface, an interior voided core area, and a porous exterior surface region, and wherein an increasing porosity vol % gradient extends from the exterior surface, through the porous exterior surface region, and throughout the interior voided core area.2. The method of claim 1 , further comprising performing surface modifications to the porous exterior surface region to encourage cell growth and adhesion thereon.3. The method of wherein forming the device for bone tissue engineering includes forming the device for bone tissue engineering utilizing a Laser Engineered ...

ORGANOPHOSPHOROUS, MULTIVALENT METAL COMPOUNDS, & POLYMER ADHESIVE INTERPENETRATING NETWORK COMPOSITIONS & METHODS

Certain small molecule amino acid phosphate compounds such as phosphoserine and certain multivalent metal compounds such as calcium phosphate containing cements have been found to have improved properties and form an interpenetrating network in the presence of a polymer that contains either an electronegative carbonyl oxygen atom of the ester group or an electronegative nitrogen atom of the amine group as the bonding sites of the polymer surfaces to the available multivalent metal ions. 1. A non-covalently bonded interpenetrating network comprising a reactive mixture of a small amino acid phosphate species , a multivalent metal compound , and a polymeric material that contains functional groups that contains electronegative atoms as the bonding sites of the polymer surfaces to the available metal ions , in an aqueous environment.2. The network as described in wherein the metal compound is divalent.3. The network as described in wherein the divalent metal compound is calcium based compound.4. The network as described in wherein the calcium based compound is calcium phosphate.6. The network as described in wherein the polymeric material is selected from the group consisting of poly(L-lactide) claim 5 , poly(D claim 5 ,L-lactide) claim 5 , polyglycolide claim 5 , poly(ε-caprolactone) claim 5 , polycarbonate claim 5 , poly(teramethylglycolic-acid) claim 5 , poly(dioxanone) claim 5 , poly(hydroxybutyrate) claim 5 , poly(hydroxyvalerate) claim 5 , poly(L-lactide-co-glycolide) claim 5 , poly(glycolide-co-trimethylene-carbonate) claim 5 , poly(glycolide-co-caprolactone) claim 5 , poly(glycolide-co-dioxanone-co-trimethylene-carbonate) claim 5 , poly(tetramethylglycolic-acid-co-dioxanone-co-trimethylene-carbonate) claim 5 , poly(glycolide-co-caprolactone-co-L-lactide-co-trimethylene-carbonate) claim 5 , poly(hydroxybutyrate-co-hydroxyvalerate) claim 5 , poly(methyl-methacrylate) claim 5 , poly(acrylate) claim 5 , polyamines claim 5 , polyamines claim 5 , polyimidazoles claim ...

Reinforced Bone Scaffold

Scaffolds for use in bone tissue engineering include a skeleton and a host component. Methods of preparation of scaffolds include identification of biodegradation properties for the skeleton and the host component. The skeleton is constructed to form a three-dimensional shape. The skeleton is constructed of a first material and has a first rate of biodegradation. The host component fills the three-dimensional shape formed by the skeleton. The host component is constructed of a second material and has a second rate of biodegradation. The first rate of biodegradation is slower than the second rate of biodegradation.

BIOIMPLANT WITH EVANESCENT COATING FILM

To provide a bioimplant capable of controlling a rate of an antibacterial agent and an antibiotic to be eluted from the coating film. An evanescent coating film made of a calcium phosphate-based material having crystallinity of 10% to 90% is formed at a predetermined area of the bioimplant and an antibacterial agent or an antibiotic is contained in the coating film to suppress adhesion of bacteria. 1. A bioimplant comprising:an implant comprising a stem portion and a neck portion; andan evanescent coating film comprising a calcium phosphate-based material disposed on a surface of the stem portion, the evanescent coating film containing an inorganic antibacterial agent,wherein the inorganic antibacterial agent comprises silver metal particles distributed in the evanescent coating film, andwherein the calcium phosphate-based material has a crystallinity of 10% to 90%.2. The bioimplant according to claim 1 , wherein the calcium phosphate-based material comprising at least one material selected from the group consisting of: hydroxyapatite (HA) claim 1 , tertiary calcium phosphate (TCP) and quaternary calcium phosphate (TeCP).3. The bioimplant according to claim 1 , wherein the thickness of the evanescent coating film is between 5 and 100 micrometers (μm).4. The bioimplant according to claim 1 , wherein an elution period of the inorganic antibacterial agent when the implant is placed in a body fluid is at least six months.5. The bioimplant according to claim 1 , wherein the implant comprises a metal or metal alloy material.6. The bioimplant according to claim 1 , wherein the evanescent coating film is formed on the implant by a thermal spraying method.7. The bioimplant according to claim 6 , wherein the thermal spraying method is selected from a group consisting of a flame spraying claim 6 , a high velocity oxygen fuel spraying claim 6 , and a plasma spraying method.8. The bioimplant according to claim 1 , wherein the evanescent coating film has an elution period of at ...

SYNTHETIC BONE GRAFTS CONSTRUCTED FROM CARBON FOAM MATERIALS

A porous, self-sustaining body useful as a scaffold for bone grafting is provided. The scaffold comprises a carbonaceous matrix comprising a continuous phase having a surface and defining a plurality of open spaces throughout the matrix. The internal and external surfaces of the matrix are coated with a layer or film selected from the group consisting of osteogenic materials, therapeutic agents, and combinations thereof. The porous body comprises organic materials and is substantially free of metals. Methods of making and using the porous self-sustaining body are also provided, along with kits for facilitating the same. 1. An implant for bone grafting in a subject comprising a porous self-sustaining body comprising:a carbonaceous matrix formed of carbon foam and/or graphite foam, said matrix comprising a continuous phase having a surface and defining a plurality of open spaces throughout said matrix, wherein said open spaces comprise pores in said matrix, anda coating immobilized on the continuous phase surface of the matrix, said coating being selected from the group consisting of osteoconductive materials, osteoinductive materials, biologics, small molecule drugs, and combinations thereof;wherein said porous body is substantially free of metal structures or supports in, on, or through the body.2. The implant of claim 1 , wherein said metal is selected from the group consisting of titanium claim 1 , titanium alloys claim 1 , steel claim 1 , tantalum claim 1 , copper claim 1 , silver claim 1 , and cobalt chromium alloy.3. The implant of claim 1 , wherein said porous body is substantially free of polypropylene claim 1 , polymethylmethacrylate claim 1 , polyethylene claim 1 , and/or polyoxymethylene.4. The implant of claim 1 , wherein said carbon or graphite foam has a porosity of at least about 80%.5. The implant of claim 1 , wherein said carbon or graphite foam has an average pore diameter of at least 50 μm.6. The implant of claim 1 , wherein said carbon or graphite ...

THREE-DIMENSIONAL PRINTED HYDROXYAPATITE COMPOSITE SCAFFOLDS FOR BONE REGENERATION, PRECURSOR COMPOSITIONS AND METHODS OF PRINTING

A three-dimensional, biocompatible scaffold precursor composition for room-temperature printing a bio-compatible polymer/hydroxyapatite composite scaffold includes a room-temperature slurry, comprising a mixture of a sold phase that includes a mixture of tetracalcium phosphate (TTCP; Ca(PO)O) and dicalcium phosphate anhydrous (DCPA; CaHPO), and a liquid phase that includes a polymer in a solvent. The solvent may be Ethanol (EtOH) or Tetrahydrofuran (THF), and the polymer may be polyvinyl butyral (PVB), polycaprolactone (PCL), or poly lactic-co-glycolic acid (PLGA). The slurry is printed at room temperature in aqueous phosphate (NaHPO) bath, which works as hardening accelerator, forming the polymer/hydroxyapatite composite scaffold 1. A three-dimensional , biocompatible scaffold precursor composition for room-temperature printing a 3D bio-compatible polymer/hydroxyapatite composite scaffold , comprising: [{'sub': 4', '4', '2', '4, 'a solid phase comprising a mixture of solid phase compounds chosen from a solid phase compound group consisting of tetracalcium phosphate (TTCP; Ca(PO)O) and dicalcium phosphate anhydrous (DCPA; CaHPO), and'}, 'a liquid phase comprising a polymer in a solvent, the solvent selected from a solvent group consisting of Ethanol (EtOH) and Tetrahydrofuran (THF), and the polymer selected from a polymer group consisting of polyvinyl butyral (PVB), polycaprolactone (PCL), and poly lactic-co-glycolic acid (PLGA); and, 'a room-temperature slurry, comprising a mixture ofa hardening accelerator that interacts with the slurry during the room-temperature printing of the polymer/hydroxyapatite composite scaffold.2. The precursor composition of claim 1 , wherein the TTCP is provided with a particle size in a range from 1 to 17 μm and the DCPA is provided with a particle size in a range from 1 to 5 μm.3. The precursor composition of claim 1 , wherein the tetracalcium phosphate (TTCP; Ca(PO)O) and dicalcium phosphate anhydrous (DCPA; CaHPO) are provided with ...